Neurosarcoidosis

Immune MONDO:0045047 Pathograph 7 Sarcoidosis Nervous System Disorder Neuroimmune Disease

Neurosarcoidosis is nervous-system involvement by sarcoidosis, with granulomatous inflammation affecting the central or peripheral nervous system. Presentations are heterogeneous and may include cranial neuropathies, neuro-ophthalmic disease, meningeal or parenchymal CNS disease, myelopathy, and peripheral nerve involvement.

Ask OpenScientist

Ask a research question about Neurosarcoidosis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Definitions
3
Pathophys.
1
Histopath.
15
Phenotypes
7
Pathograph
4
Genes
4
Treatments
5
Subtypes
2
Trials
96
References
2
Deep Research
📘

Definitions

1
Neurosarcoidosis Consortium diagnostic definition
Consensus criteria classify possible, probable, and definite central or peripheral nervous system sarcoidosis after excluding infectious, malignant, and other alternate causes; nonneural biopsy supports probable neurosarcoidosis and neural tissue biopsy supports definite disease.
DIAGNOSTIC_CRITERIA
Show evidence (2 references)
PMID:30167654 SUPPORT Human Clinical
"The proposed consensus diagnostic criteria, which reflect current knowledge, provide definitions for possible, probable, and definite central and peripheral nervous system sarcoidosis."
The consensus statement defines the diagnostic categories for neurosarcoidosis.
PMID:30167654 SUPPORT Human Clinical
"Also emphasized is the need for biopsy, whenever feasible and advisable according to clinical context and affected anatomy, of nonneural tissue to document the presence of systemic sarcoidosis and support a diagnosis of probable neurosarcoidosis or of neural tissue to support a diagnosis of..."
The diagnostic definition distinguishes probable from definite disease by biopsy site.
◆

Subtypes

5
Cranial neuropathy-predominant neurosarcoidosis
Neurosarcoidosis presenting predominantly with cranial nerve involvement, often including facial, optic, abducens, trigeminal, or other cranial neuropathies.
Show evidence (1 reference)
PMID:40564079 SUPPORT Human Clinical
"NS was subdivided into chronic headache (n = 11; 36.7%), cranial neuropathy (n = 7; 24.1%), myelitis (n = 4; 13.8%), peripheral neuropathy (n = 3; 10.3%), cranial neuropathy with chronic headache (n = 3; 10.3%) and aseptic meningitis (n = 2; 6.9%)."
The cohort explicitly separates a cranial neuropathy clinical subtype.
Meningeal and parenchymal CNS neurosarcoidosis
CNS-predominant neurosarcoidosis with meningeal, parenchymal, headache, seizure, hydrocephalus, or cognitive manifestations.
Show evidence (1 reference)
PMID:32487903 SUPPORT Human Clinical
"central nervous system sarcoidosis occurs in well-defined presentations that can be classified as cranial neuropathies, meningeal disease, brain parenchymal (including pituitary-hypothalamic) disease, and spinal cord disease."
This review classifies meningeal and parenchymal CNS presentations as major neurosarcoidosis forms.
Spinal cord neurosarcoidosis
Neurosarcoidosis with spinal cord inflammation, including myelitis and enhancing intramedullary or leptomeningeal spinal cord lesions.
Show evidence (1 reference)
PMID:32404428 SUPPORT Human Clinical
"Twenty patients (36%) had spinal cord involvement on MRI."
The longitudinal cohort identifies spinal cord involvement as a common disease compartment.
Peripheral nervous system neurosarcoidosis
Neurosarcoidosis involving peripheral nerves, including sensory or sensorimotor neuropathy and mononeuropathies.
Show evidence (1 reference)
PMID:32404428 SUPPORT Human Clinical
"Manifestations of PNS involvement included distal sensorimotor polyneuropathy and mononeuropathies."
The cohort describes peripheral nerve involvement as part of the neurosarcoidosis spectrum.
Hypothalamic-pituitary neurosarcoidosis
Neurosarcoidosis involving the hypothalamus, pituitary stalk, or pituitary gland, often with persistent endocrine dysfunction.
Show evidence (1 reference)
PMID:22753675 SUPPORT Human Clinical
"All but two patients had anterior pituitary dysfunction, 12 patients presented with diabetes insipidus."
The multicenter cohort identifies hypothalamic-pituitary involvement as a neurosarcoidosis localization.
⚙

Pathophysiology

3
Antigen Presentation and Th1-Th17 Activation
Sarcoidosis susceptibility is shaped by antigen presentation and enhanced Th1/Th17 immune activation, producing cytokine signals that initiate and expand granulomatous inflammation before tissue-specific nervous-system injury occurs.
T-helper 1 cell link T-helper 17 cell link macrophage link
antigen processing and presentation link ↑ INCREASED T cell activation link ↑ INCREASED cytokine production link ↑ INCREASED cell surface receptor signaling pathway via JAK-STAT link ↑ INCREASED
Downstream
Nervous System Granulomatous Inflammation Activated Th1/Th17 and macrophage cytokine signaling promotes sarcoid granuloma formation and expansion in susceptible tissues, including neural compartments in neurosarcoidosis.
Show evidence (1 reference)
PMID:41054684 SUPPORT Human Clinical
"Meanwhile, enhanced Th17 production stimulates the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway, ultimately leading to granuloma expansion."
Supports Th17-associated JAK-STAT signaling as a granuloma-expansion mechanism in sarcoidosis.
Nervous System Granulomatous Inflammation
Sarcoid granulomatous inflammation involves neural or meningeal tissue, producing heterogeneous central and peripheral nervous system presentations.
macrophage link CD4-positive helper T cell link
inflammatory response link ↑ INCREASED adaptive immune response link ↑ INCREASED macrophage activation link ↑ INCREASED granuloma formation link ↑ INCREASED
nervous system link
Downstream
Neurologic Dysfunction Granulomatous inflammation in neural, meningeal, or cranial-nerve sites causes focal or diffuse neurologic manifestations.
Show evidence (2 references)
ORPHA:797 SUPPORT
"A rare multisystemic, autoinflammatory disorder of unknown etiology characterized by the formation of immune, non-caseating granulomas in any organ(s), leading to variable clinical symptoms and severity."
Orphanet establishes the systemic sarcoid granulomatous process that can involve the nervous system.
PMID:30167654 SUPPORT Human Clinical
"Diverse disease presentations and lack of specificity of relevant diagnostic tests contribute to diagnostic uncertainty."
The consensus statement emphasizes clinical heterogeneity from nervous-system involvement.
Neurologic Dysfunction
Downstream dysfunction includes cranial neuropathy, visual pathway involvement, meningeal or parenchymal CNS disease, and peripheral nerve manifestations.
brain link spinal cord link peripheral nervous system link
Show evidence (1 reference)
PMID:30167654 SUPPORT Human Clinical
"The work of this collaboration included a review of the manifestations of neurosarcoidosis and the establishment of an approach to the diagnosis of this disorder."
The consensus criteria are built around the diverse manifestations of neurosarcoidosis.
✶

Histopathology

1
Non-caseating granulomatous inflammation
Non-caseating granulomatous inflammation in neural tissue supports definite neurosarcoidosis, while extraneural biopsy evidence of systemic sarcoidosis supports probable neurosarcoidosis in the appropriate clinical context.
Show evidence (2 references)
ORPHA:797 SUPPORT
"A rare multisystemic, autoinflammatory disorder of unknown etiology characterized by the formation of immune, non-caseating granulomas in any organ(s), leading to variable clinical symptoms and severity."
Orphanet identifies non-caseating granulomas as the core sarcoidosis histopathologic process.
PMID:30167654 SUPPORT Human Clinical
"Also emphasized is the need for biopsy, whenever feasible and advisable according to clinical context and affected anatomy, of nonneural tissue to document the presence of systemic sarcoidosis and support a diagnosis of probable neurosarcoidosis or of neural tissue to support a diagnosis of..."
The consensus criteria tie probable and definite neurosarcoidosis classification to biopsy confirmation of sarcoidosis.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Neurosarcoidosis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

15
Endocrine 1
Diabetes Insipidus Diabetes insipidus (HP:0000873)
Show evidence (1 reference)
PMID:22753675 SUPPORT Human Clinical
"All but two patients had anterior pituitary dysfunction, 12 patients presented with diabetes insipidus."
Diabetes insipidus was a common endocrine presentation in hypothalamic-pituitary sarcoidosis.
Head and Neck 1
Facial Palsy Facial palsy (HP:0010628)
Show evidence (1 reference)
PMID:33110001 SUPPORT Human Clinical
"Neuro-ophthalmic findings included optic neuropathy in 11 (50%); proptosis/orbital inflammation in 5 (23%); abducens palsy in 5 (23%); trochlear palsy, trigeminal distribution numbness, and bitemporal hemianopia in 2 each (9%); and oculomotor palsy, facial palsy, optic perineuritis, dorsal..."
The series lists facial palsy among neuro-ophthalmic manifestations.
Immune 2
Myelitis OCCASIONAL Myelitis (HP:0012486)
Show evidence (1 reference)
PMID:40564079 SUPPORT Human Clinical
"NS was subdivided into chronic headache (n = 11; 36.7%), cranial neuropathy (n = 7; 24.1%), myelitis (n = 4; 13.8%), peripheral neuropathy (n = 3; 10.3%), cranial neuropathy with chronic headache (n = 3; 10.3%) and aseptic meningitis (n = 2; 6.9%)."
Myelitis was observed in 13.8% of this neurosarcoidosis cohort.
Meningitis OCCASIONAL Meningitis (HP:0001287)
Show evidence (1 reference)
PMID:28601860 SUPPORT Human Clinical
"Cranial neuropathy was the most common type of neurological disease (5 patients; 45%) followed by peripheral neuropathy (3 patients; 27%), and meningitis (3 patients; 27%)."
Meningitis was one of the most common neurologic disease types in this population-based cohort.
Musculoskeletal 1
Muscle Weakness FREQUENT Muscle weakness (HP:0001324)
Show evidence (1 reference)
DOI:10.1038/s41598-023-33631-z SUPPORT Human Clinical
"Cranial neuropathies (38%), motor deficit (32%), headache (16%), and pituitary dysfunction (12%) were the most common presenting features."
Motor deficit was a frequent presenting feature in this diagnostic cohort.
Nervous System 7
Headache FREQUENT Headache (HP:0002315)
Show evidence (1 reference)
PMID:40564079 SUPPORT Human Clinical
"NS was subdivided into chronic headache (n = 11; 36.7%), cranial neuropathy (n = 7; 24.1%), myelitis (n = 4; 13.8%), peripheral neuropathy (n = 3; 10.3%), cranial neuropathy with chronic headache (n = 3; 10.3%) and aseptic meningitis (n = 2; 6.9%)."
Chronic headache met the frequent range in this cohort.
Cranial Neuropathy OCCASIONAL Cranial nerve paralysis (HP:0006824)
Show evidence (1 reference)
PMID:40564079 SUPPORT Human Clinical
"NS was subdivided into chronic headache (n = 11; 36.7%), cranial neuropathy (n = 7; 24.1%), myelitis (n = 4; 13.8%), peripheral neuropathy (n = 3; 10.3%), cranial neuropathy with chronic headache (n = 3; 10.3%) and aseptic meningitis (n = 2; 6.9%)."
Cranial neuropathy was reported in the occasional range as a subtype-defining presentation.
Peripheral Neuropathy OCCASIONAL Peripheral neuropathy (HP:0009830)
Show evidence (1 reference)
PMID:40564079 SUPPORT Human Clinical
"NS was subdivided into chronic headache (n = 11; 36.7%), cranial neuropathy (n = 7; 24.1%), myelitis (n = 4; 13.8%), peripheral neuropathy (n = 3; 10.3%), cranial neuropathy with chronic headache (n = 3; 10.3%) and aseptic meningitis (n = 2; 6.9%)."
Peripheral neuropathy was reported in 10.3% of patients in this cohort.
Small Fiber Neuropathy FREQUENT Peripheral neuropathy (HP:0009830)
HPO does not provide a pre-coordinated small fiber neuropathy term in the local ontology release; the more specific clinical label is retained in preferred_term while mapping to peripheral neuropathy.
Show evidence (1 reference)
PMID:41218636 SUPPORT Human Clinical
"An important cause of pain in patients with sarcoidosis is small fiber neuropathy (SFN), with an estimated prevalence of 33 to 86%."
This review supports small fiber neuropathy as a frequent sarcoidosis-associated peripheral nerve manifestation.
Hydrocephalus Hydrocephalus (HP:0000238)
Show evidence (1 reference)
PMID:32404428 SUPPORT Human Clinical
"Neurologic manifestations commonly include cranial neuropathies, aseptic meningitis, peripheral neuropathy, myelopathy, intraparenchymal mass lesions, and hydrocephalus, all of which can lead to significant morbidity and mortality."
The longitudinal study lists hydrocephalus among common neurologic manifestations.
Seizure OCCASIONAL Seizure (HP:0001250)
Show evidence (1 reference)
DOI:10.1002/brb3.3443 SUPPORT Human Clinical
"NS was the initial presentation in 78% of patients, with cranial nerve involvement (36%), medullary symptoms (23%), and seizures (21%)."
Seizures were an occasional initial manifestation in the national multicenter cohort.
Cognitive Impairment OCCASIONAL Cognitive impairment (HP:0100543)
Show evidence (1 reference)
PMID:40769406 SUPPORT Human Clinical
"Reported prevalence varies widely: ∼30 % in AAV, 0-35 % in sarcoidosis, 10-80 % in pSS, 8-65 % in SSc, and 30-100 % in BD."
This review supports cognitive impairment as a sarcoidosis-associated cognitive phenotype in the occasional frequency range.
Other 3
Optic Neuropathy Optic neuropathy (HP:0001138)
Show evidence (1 reference)
PMID:33110001 SUPPORT Human Clinical
"Neuro-ophthalmic findings included optic neuropathy in 11 (50%); proptosis/orbital inflammation in 5 (23%); abducens palsy in 5 (23%); trochlear palsy, trigeminal distribution numbness, and bitemporal hemianopia in 2 each (9%); and oculomotor palsy, facial palsy, optic perineuritis, dorsal..."
The case series directly lists optic neuropathy among neuro-ophthalmic manifestations.
Abducens Palsy Abducens palsy (HP:0006897)
Show evidence (1 reference)
PMID:33110001 SUPPORT Human Clinical
"Neuro-ophthalmic findings included optic neuropathy in 11 (50%); proptosis/orbital inflammation in 5 (23%); abducens palsy in 5 (23%); trochlear palsy, trigeminal distribution numbness, and bitemporal hemianopia in 2 each (9%); and oculomotor palsy, facial palsy, optic perineuritis, dorsal..."
The neuro-ophthalmology cohort reports abducens palsy as a sarcoidosis-associated manifestation.
Hypopituitarism Hypopituitarism (HP:0040075)
Show evidence (1 reference)
PMID:22753675 SUPPORT Human Clinical
"All but two patients had anterior pituitary dysfunction, 12 patients presented with diabetes insipidus."
Anterior pituitary dysfunction in hypothalamic-pituitary sarcoidosis maps to hypopituitarism.
🧬

Genetic Associations

4
HLA-DRB1 (HLA class II alleles modify sarcoidosis clinical course and antigen presentation.)
Show evidence (1 reference)
PMID:27662826 SUPPORT Human Clinical
"Only the HLA DRB1*03 allele was significantly associated with disease resolution (21.2% vs 4.9% for chronic disease; RR = 0.35; P < .01 after Bonferroni correction)."
Supports HLA-DRB1 allelic variation as a genetic modifier of sarcoidosis clinical course.
BTNL2 (Sarcoidosis susceptibility locus affecting T cell co-stimulation.)
Show evidence (1 reference)
PMID:26164297 SUPPORT Human Clinical
"Genome-wide genetic screening approaches revealed a number of novel susceptibility factors for sarcoidosis, some of which are very likely to affect granuloma formation. A splicing variant in the BTNL2 gene had first been reported with regards to sarcoidosis by Valentonyte et al. in a German..."
Supports BTNL2 as a sarcoidosis susceptibility gene connected to granuloma biology.
ANXA11 (Sarcoidosis susceptibility locus linked to granuloma stability and apoptosis regulation.)
Show evidence (1 reference)
PMID:26164297 SUPPORT Human Clinical
"Based on a genome-wide association study (GWAS), variants in the ANXA11 gene which codes for Annexin 11 were found to be associated with sarcoidosis 44 and confirmed in independent populations of German, Czech, Portuguese and European and African American origin 37, 45-48."
Supports ANXA11 as a replicated sarcoidosis susceptibility locus.
NOD2 (Monogenic sarcoidosis-spectrum granulomatous disease gene in Blau syndrome.)
Show evidence (1 reference)
PMID:32618442 SUPPORT Human Clinical
"Heterozygous mutations in nucleotide-binding oligomerization domain 2 (NOD2) were identified as the cause of Blau Syndrome onset."
Supports NOD2 as the causative gene for a sarcoidosis-spectrum autoinflammatory granulomatosis.
💊

Treatments

4
High-dose glucocorticoids
Action: Pharmacotherapy NCIT:C15986
Agent: corticosteroid ↗ prednisone ↗
High-dose glucocorticoids such as prednisone or intravenous methylprednisolone are commonly used as initial therapy, but long-term toxicity and relapse during taper often necessitate steroid-sparing agents.
Mechanism Target:
INHIBITS Nervous System Granulomatous Inflammation — Glucocorticoids suppress the granulomatous inflammatory process.
Show evidence (1 reference)
PMID:28601860 SUPPORT Human Clinical
"Almost all patients had a good response to initial treatment with high-dose glucocorticoids, often initially 1 gram methylprednisolone daily for 3 to 5 days, or prednisone, 1 mg/kg body weight as initial dose."
Clinical response to high-dose glucocorticoids supports inhibition of active inflammatory disease.
Show evidence (1 reference)
PMID:28601860 SUPPORT Human Clinical
"All patients received high-dose glucocorticoids as initial treatment and almost all responded to this therapy."
Supports glucocorticoids as common initial treatment with frequent initial response.
Conventional steroid-sparing immunosuppression
Action: Pharmacotherapy NCIT:C15986
Agent: methotrexate ↗ azathioprine ↗ immunosuppressant ↗
Methotrexate, azathioprine, mycophenolate mofetil, and related immunosuppressants are used when glucocorticoid taper fails or prolonged steroid exposure is undesirable.
Mechanism Target:
INHIBITS Nervous System Granulomatous Inflammation — Steroid-sparing immunosuppressants reduce adaptive immune activity sustaining granulomatous inflammation.
Show evidence (1 reference)
PMID:28601860 SUPPORT Human Clinical
"Several disease-modifying anti-rheumatic disease drugs (DMARDs), including methotrexate, mycophenolate mofetil, hydroxychloroquine and azathioprine, were used in this cohort as glucocorticoid-sparing agents after failure of glucocorticoids taper."
Steroid-sparing DMARD use supports immunosuppression as a treatment mechanism.
Show evidence (1 reference)
PMID:28601860 SUPPORT Human Clinical
"Several disease-modifying anti-rheumatic disease drugs (DMARDs), including methotrexate, mycophenolate mofetil, hydroxychloroquine and azathioprine, were used in this cohort as glucocorticoid-sparing agents after failure of glucocorticoids taper."
The cohort documents conventional immunosuppressants used as steroid-sparing agents.
Infliximab
Action: Pharmacotherapy NCIT:C15986
Agent: infliximab ↗
TNF-alpha blockade with infliximab is used for refractory or severe neurosarcoidosis and has cohort evidence for stabilization or improvement.
Mechanism Target:
INHIBITS Nervous System Granulomatous Inflammation — TNF-alpha blockade targets a cytokine axis required for granulomatous inflammation.
Show evidence (1 reference)
PMID:32404428 SUPPORT Human Clinical
"This robust response is because of TNFα's critical role in the granuloma formation and supported by the high recurrence rate seen after stopping the medication."
The cohort explicitly relates infliximab response to TNF-alpha's role in granuloma biology.
Show evidence (3 references)
PMID:32404428 SUPPORT Human Clinical
"Infliximab was the most effective therapy, with 87% of patients remaining stable or improving on infliximab."
The longitudinal cohort supports infliximab effectiveness in neurosarcoidosis.
PMID:28260120 SUPPORT Human Clinical
"At 6 months after initiation of infliximab, six patients obtained complete remission (33%), ten attained partial remission (56%), and two had stable disease (11%)."
A refractory neurosarcoidosis cohort reports remission or stability after infliximab.
DOI:10.1002/acn3.51968 SUPPORT Human Clinical
"Infliximab demonstrated potential improvement in clinical outcomes for patients with refractory neurosarcoidosis and showed potential for reducing the dosage of concurrent corticosteroids."
The systematic review provides pooled outcome support for infliximab in neurosarcoidosis.
Adalimumab
Action: Pharmacotherapy NCIT:C15986
Agent: adalimumab ↗
Adalimumab is an alternative TNF-alpha inhibitor with limited case-series evidence for clinical and radiographic response in neurosarcoidosis.
Mechanism Target:
INHIBITS Nervous System Granulomatous Inflammation — TNF-alpha blockade targets granulomatous inflammatory signaling.
Show evidence (1 reference)
PMID:38640580 SUPPORT Human Clinical
"We discovered ten neurosarcoidosis patients who were on an alternative TNA-alpha inhibitor, adalimumab."
The case series identifies adalimumab as an alternative TNF-alpha inhibitor used in neurosarcoidosis.
Show evidence (1 reference)
PMID:38640580 SUPPORT Human Clinical
"Eight patients had a positive response clinically and radiographically to adalimumab."
A small case series reports clinical and radiographic response to adalimumab.
🔬

Biochemical Markers

5
CSF Pleocytosis (INCREASED)
Context: CSF pleocytosis supports CNS inflammation in neurosarcoidosis, especially in meningeal, spinal cord, mass-lesion, and some cranial neuropathy presentations.
Show evidence (1 reference)
PMID:28601860 SUPPORT Human Clinical
"CSF pleocytosis and high CSF protein level were also observed in the patient with intra-medullary spinal cord sarcoidosis, the patient with intra-cranial mass lesion and some patients with cranial neuropathy, but not in patients with peripheral neuropathy."
The cohort links CSF pleocytosis to CNS neurosarcoidosis compartments.
Elevated CSF Protein (INCREASED)
Context: Elevated CSF protein is a common supportive inflammatory finding, but it is not specific and must be interpreted with imaging, biopsy, and exclusion of mimics.
Show evidence (1 reference)
PMID:32404428 SUPPORT Human Clinical
"An elevated CSF protein level (>50 mg/dL) was present in 16 of 29 patients (55%), and oligoclonal bands were present in 6 of 21 patients (29%)."
The longitudinal cohort quantifies elevated CSF protein in neurosarcoidosis patients.
Elevated Soluble Interleukin-2 Receptor (INCREASED)
Context: Serum or CSF soluble interleukin-2 receptor may support inflammatory neurosarcoidosis evaluation, especially when differentiating from multiple sclerosis or other mimics.
Show evidence (1 reference)
DOI:10.3389/fneur.2023.1135392 SUPPORT Human Clinical
"Compared to MS, patients with neurosarcoidosis showed more frequently an increased Qalb and CSF lactate levels as well as increased serum and CSF levels of sIL-2R, but a lower frequency of intrathecal IgG synthesis and positive MRZ reaction."
This cohort supports increased soluble IL-2 receptor as part of the inflammatory biomarker profile.
Angiotensin-Converting Enzyme (INCREASED)
Context: Serum ACE is a traditional supportive sarcoidosis biomarker and CSF ACE has limited sensitivity but high specificity in selected probable CNS neurosarcoidosis cohorts.
Show evidence (2 references)
PMID:32354749 SUPPORT Human Clinical
"Serum ACE levels were elevated in 51% of patients but in only 14% of those with isolated neurosarcoidosis."
This neurosarcoidosis cohort supports serum ACE elevation as a traditional but imperfect biomarker.
PMID:12405488 SUPPORT Human Clinical
"At this value, the sensitivity and specificity of CSF-ACE activity was 55% and 94%, respectively."
This study supports CSF ACE as a high-specificity, limited-sensitivity biochemical marker in probable CNS neurosarcoidosis.
Elevated Neurofilament Light Chain (INCREASED)
Context: Elevated cerebrospinal fluid or plasma neurofilament light chain reflects axonal injury and correlates with inflammatory MRI activity in neurosarcoidosis.
Show evidence (1 reference)
PMID:33672795 SUPPORT Human Clinical
"NFL levels in cerebrospinal fluid and plasma are significantly higher in neurosarcoidosis patients compared to extra-neurologic patients and healthy controls, and the levels correlate to the extent of inflammation on MRI."
This study supports neurofilament light chain as a biomarker of neuroaxonal injury and inflammatory activity.
🔬

Clinical Trials

2
NCT02920710 PHASE_IV WITHDRAWN
ACTHAR gel study for severe central nervous system sarcoidosis.
Show evidence (1 reference)
clinicaltrials:NCT02920710 SUPPORT
"This study aims to provide evidence for effectiveness of ACTHAR gel in CNS sarcoidosis, and provide information about its safety and tolerability"
ClinicalTrials.gov describes an interventional ACTHAR study specific to CNS sarcoidosis.
NCT04911348 UNKNOWN
Multicenter retrospective study of initial presentation and disease course in neurosarcoidosis.
Show evidence (1 reference)
clinicaltrials:NCT04911348 SUPPORT
"Using retrospective data from patients diagnosed with neurosarcoidosis in three French referral centers for neuro-inflammation, the investigators aim to determine patterns of disease course, according to the initial presentation and the treatments used."
The trial registry describes a neurosarcoidosis-specific disease-course study.
{ }

Source YAML

click to show 
name: Neurosarcoidosis
creation_date: "2026-05-16T11:52:47Z"
updated_date: "2026-05-16T14:27:49Z"
category: Immune
datasets: []
description: >-
  Neurosarcoidosis is nervous-system involvement by sarcoidosis, with
  granulomatous inflammation affecting the central or peripheral nervous system.
  Presentations are heterogeneous and may include cranial neuropathies,
  neuro-ophthalmic disease, meningeal or parenchymal CNS disease, myelopathy, and
  peripheral nerve involvement.
disease_term:
  preferred_term: neurosarcoidosis
  term:
    id: MONDO:0045047
    label: neurosarcoidosis
parents:
- Sarcoidosis
- Nervous System Disorder
- Neuroimmune Disease
prevalence:
- population: Northern Spain
  percentage: 1.1 per 1,000,000 people annual incidence
  evidence:
  - reference: PMID:40564079
    reference_title: Epidemiology, Clinical Features and Treatment of Neurosarcoidosis in Northern Spain.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The annual incidence of NS during the study period was 1.1 per 1,000,000 people."
    explanation: A population-based Northern Spain cohort quantified annual neurosarcoidosis incidence.
- population: Olmsted County sarcoidosis cohort
  percentage: 3% of patients with sarcoidosis
  evidence:
  - reference: PMID:28601860
    reference_title: "Characteristics and Long-Term Outcome of Neurosarcoidosis: A Population-Based Study from 1976-2013."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological involvement by sarcoidosis occurred in 11 patients (3% of all patients with sarcoidosis)."
    explanation: This population-based sarcoidosis cohort estimates nervous-system involvement among sarcoidosis patients.
has_subtypes:
- name: Cranial Neuropathy
  display_name: Cranial neuropathy-predominant neurosarcoidosis
  description: >-
    Neurosarcoidosis presenting predominantly with cranial nerve involvement,
    often including facial, optic, abducens, trigeminal, or other cranial
    neuropathies.
  evidence:
  - reference: PMID:40564079
    reference_title: Epidemiology, Clinical Features and Treatment of Neurosarcoidosis in Northern Spain.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NS was subdivided into chronic headache (n = 11; 36.7%), cranial
      neuropathy (n = 7; 24.1%), myelitis (n = 4; 13.8%), peripheral neuropathy
      (n = 3; 10.3%), cranial neuropathy with chronic headache (n = 3; 10.3%)
      and aseptic meningitis (n = 2; 6.9%).
    explanation: The cohort explicitly separates a cranial neuropathy clinical subtype.
- name: Meningeal CNS
  display_name: Meningeal and parenchymal CNS neurosarcoidosis
  description: >-
    CNS-predominant neurosarcoidosis with meningeal, parenchymal, headache,
    seizure, hydrocephalus, or cognitive manifestations.
  evidence:
  - reference: PMID:32487903
    reference_title: Sarcoidosis and the Nervous System.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      central nervous system sarcoidosis occurs in well-defined presentations
      that can be classified as cranial neuropathies, meningeal disease, brain
      parenchymal (including pituitary-hypothalamic) disease, and spinal cord
      disease.
    explanation: This review classifies meningeal and parenchymal CNS presentations as major neurosarcoidosis forms.
- name: Myelitis
  display_name: Spinal cord neurosarcoidosis
  description: >-
    Neurosarcoidosis with spinal cord inflammation, including myelitis and
    enhancing intramedullary or leptomeningeal spinal cord lesions.
  evidence:
  - reference: PMID:32404428
    reference_title: "Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Twenty patients (36%) had spinal cord involvement on MRI.
    explanation: The longitudinal cohort identifies spinal cord involvement as a common disease compartment.
- name: Peripheral Neuropathy
  display_name: Peripheral nervous system neurosarcoidosis
  description: >-
    Neurosarcoidosis involving peripheral nerves, including sensory or
    sensorimotor neuropathy and mononeuropathies.
  evidence:
  - reference: PMID:32404428
    reference_title: "Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Manifestations of PNS involvement included distal sensorimotor
      polyneuropathy and mononeuropathies.
    explanation: The cohort describes peripheral nerve involvement as part of the neurosarcoidosis spectrum.
- name: Hypothalamic-Pituitary
  display_name: Hypothalamic-pituitary neurosarcoidosis
  description: >-
    Neurosarcoidosis involving the hypothalamus, pituitary stalk, or pituitary
    gland, often with persistent endocrine dysfunction.
  evidence:
  - reference: PMID:22753675
    reference_title: "Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All but two patients had anterior pituitary dysfunction, 12 patients
      presented with diabetes insipidus.
    explanation: The multicenter cohort identifies hypothalamic-pituitary involvement as a neurosarcoidosis localization.
definitions:
- name: Neurosarcoidosis Consortium diagnostic definition
  definition_type: DIAGNOSTIC_CRITERIA
  description: >-
    Consensus criteria classify possible, probable, and definite central or
    peripheral nervous system sarcoidosis after excluding infectious,
    malignant, and other alternate causes; nonneural biopsy supports probable
    neurosarcoidosis and neural tissue biopsy supports definite disease.
  evidence:
  - reference: PMID:30167654
    reference_title: "Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The proposed consensus diagnostic criteria, which reflect current
      knowledge, provide definitions for possible, probable, and definite
      central and peripheral nervous system sarcoidosis.
    explanation: The consensus statement defines the diagnostic categories for neurosarcoidosis.
  - reference: PMID:30167654
    reference_title: "Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Also emphasized is the need for biopsy, whenever feasible and advisable
      according to clinical context and affected anatomy, of nonneural tissue to
      document the presence of systemic sarcoidosis and support a diagnosis of
      probable neurosarcoidosis or of neural tissue to support a diagnosis of
      definite neurosarcoidosis.
    explanation: The diagnostic definition distinguishes probable from definite disease by biopsy site.
pathophysiology:
- name: Antigen Presentation and Th1-Th17 Activation
  description: >-
    Sarcoidosis susceptibility is shaped by antigen presentation and enhanced
    Th1/Th17 immune activation, producing cytokine signals that initiate and
    expand granulomatous inflammation before tissue-specific nervous-system
    injury occurs.
  cell_types:
  - preferred_term: T-helper 1 cell
    term:
      id: CL:0000545
      label: T-helper 1 cell
  - preferred_term: T-helper 17 cell
    term:
      id: CL:0000899
      label: T-helper 17 cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: antigen processing and presentation
    modifier: INCREASED
    term:
      id: GO:0019882
      label: antigen processing and presentation
  - preferred_term: T cell activation
    modifier: INCREASED
    term:
      id: GO:0042110
      label: T cell activation
  - preferred_term: cytokine production
    modifier: INCREASED
    term:
      id: GO:0001816
      label: cytokine production
  - preferred_term: cell surface receptor signaling pathway via JAK-STAT
    modifier: INCREASED
    term:
      id: GO:0007259
      label: cell surface receptor signaling pathway via JAK-STAT
  downstream:
  - target: Nervous System Granulomatous Inflammation
    description: >-
      Activated Th1/Th17 and macrophage cytokine signaling promotes sarcoid
      granuloma formation and expansion in susceptible tissues, including neural
      compartments in neurosarcoidosis.
    evidence:
    - reference: PMID:41054684
      reference_title: A Fulminant Case of Refractory Sarcoidosis Triggered by Infliximab-Neutralizing Antibodies.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        An abnormal T regulatory response, in parallel with an enhanced Th1
        response, results in the release of cytokines, including IL-2, IL-12,
        IL-18, tumor necrosis factor-alpha (TNF-α), and interferon-gamma
        (IFN-γ), which initiates granuloma formation.
      explanation: >-
        This review describes the Th1 cytokine axis that initiates sarcoid
        granuloma formation upstream of tissue-specific involvement.
  evidence:
  - reference: PMID:41054684
    reference_title: A Fulminant Case of Refractory Sarcoidosis Triggered by Infliximab-Neutralizing Antibodies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Meanwhile, enhanced Th17 production stimulates the Janus kinase-signal
      transducer and activator of transcription (JAK-STAT) signaling pathway,
      ultimately leading to granuloma expansion.
    explanation: >-
      Supports Th17-associated JAK-STAT signaling as a granuloma-expansion
      mechanism in sarcoidosis.
- name: Nervous System Granulomatous Inflammation
  description: >-
    Sarcoid granulomatous inflammation involves neural or meningeal tissue,
    producing heterogeneous central and peripheral nervous system presentations.
  locations:
  - preferred_term: nervous system
    term:
      id: UBERON:0001016
      label: nervous system
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: CD4-positive helper T cell
    term:
      id: CL:0000492
      label: CD4-positive helper T cell
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: adaptive immune response
    modifier: INCREASED
    term:
      id: GO:0002250
      label: adaptive immune response
  - preferred_term: macrophage activation
    modifier: INCREASED
    term:
      id: GO:0042116
      label: macrophage activation
  - preferred_term: granuloma formation
    modifier: INCREASED
    term:
      id: GO:0002432
      label: granuloma formation
  downstream:
  - target: Neurologic Dysfunction
    description: >-
      Granulomatous inflammation in neural, meningeal, or cranial-nerve sites
      causes focal or diffuse neurologic manifestations.
    evidence:
    - reference: PMID:32404428
      reference_title: "Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Neurologic manifestations commonly include cranial neuropathies, aseptic
        meningitis, peripheral neuropathy, myelopathy, intraparenchymal mass
        lesions, and hydrocephalus, all of which can lead to significant morbidity
        and mortality.
      explanation: The longitudinal cohort links neurosarcoidosis inflammation to focal neurologic manifestations.
  evidence:
  - reference: ORPHA:797
    reference_title: Sarcoidosis
    supports: SUPPORT
    snippet: >-
      A rare multisystemic, autoinflammatory disorder of unknown etiology
      characterized by the formation of immune, non-caseating granulomas in any
      organ(s), leading to variable clinical symptoms and severity.
    explanation: Orphanet establishes the systemic sarcoid granulomatous process that can involve the nervous system.
  - reference: PMID:30167654
    reference_title: "Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diverse disease presentations and lack of specificity of relevant
      diagnostic tests contribute to diagnostic uncertainty.
    explanation: The consensus statement emphasizes clinical heterogeneity from nervous-system involvement.
- name: Neurologic Dysfunction
  description: >-
    Downstream dysfunction includes cranial neuropathy, visual pathway
    involvement, meningeal or parenchymal CNS disease, and peripheral nerve
    manifestations.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  - preferred_term: peripheral nervous system
    term:
      id: UBERON:0000010
      label: peripheral nervous system
  evidence:
  - reference: PMID:30167654
    reference_title: "Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The work of this collaboration included a review of the manifestations of
      neurosarcoidosis and the establishment of an approach to the diagnosis of
      this disorder.
    explanation: The consensus criteria are built around the diverse manifestations of neurosarcoidosis.
phenotypes:
- name: Headache
  subtype: Meningeal CNS
  category: Neurologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:40564079
    reference_title: Epidemiology, Clinical Features and Treatment of Neurosarcoidosis in Northern Spain.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NS was subdivided into chronic headache (n = 11; 36.7%), cranial
      neuropathy (n = 7; 24.1%), myelitis (n = 4; 13.8%), peripheral neuropathy
      (n = 3; 10.3%), cranial neuropathy with chronic headache (n = 3; 10.3%)
      and aseptic meningitis (n = 2; 6.9%).
    explanation: Chronic headache met the frequent range in this cohort.
- name: Cranial Neuropathy
  subtype: Cranial Neuropathy
  category: Neurologic
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Cranial neuropathy
    term:
      id: HP:0006824
      label: Cranial nerve paralysis
  evidence:
  - reference: PMID:40564079
    reference_title: Epidemiology, Clinical Features and Treatment of Neurosarcoidosis in Northern Spain.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NS was subdivided into chronic headache (n = 11; 36.7%), cranial
      neuropathy (n = 7; 24.1%), myelitis (n = 4; 13.8%), peripheral neuropathy
      (n = 3; 10.3%), cranial neuropathy with chronic headache (n = 3; 10.3%)
      and aseptic meningitis (n = 2; 6.9%).
    explanation: Cranial neuropathy was reported in the occasional range as a subtype-defining presentation.
- name: Myelitis
  subtype: Myelitis
  category: Neurologic
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Myelitis
    term:
      id: HP:0012486
      label: Myelitis
  evidence:
  - reference: PMID:40564079
    reference_title: Epidemiology, Clinical Features and Treatment of Neurosarcoidosis in Northern Spain.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NS was subdivided into chronic headache (n = 11; 36.7%), cranial
      neuropathy (n = 7; 24.1%), myelitis (n = 4; 13.8%), peripheral neuropathy
      (n = 3; 10.3%), cranial neuropathy with chronic headache (n = 3; 10.3%)
      and aseptic meningitis (n = 2; 6.9%).
    explanation: Myelitis was observed in 13.8% of this neurosarcoidosis cohort.
- name: Peripheral Neuropathy
  subtype: Peripheral Neuropathy
  category: Neurologic
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:40564079
    reference_title: Epidemiology, Clinical Features and Treatment of Neurosarcoidosis in Northern Spain.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NS was subdivided into chronic headache (n = 11; 36.7%), cranial
      neuropathy (n = 7; 24.1%), myelitis (n = 4; 13.8%), peripheral neuropathy
      (n = 3; 10.3%), cranial neuropathy with chronic headache (n = 3; 10.3%)
      and aseptic meningitis (n = 2; 6.9%).
    explanation: Peripheral neuropathy was reported in 10.3% of patients in this cohort.
- name: Small Fiber Neuropathy
  subtype: Peripheral Neuropathy
  category: Neurologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Small fiber neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  notes: >-
    HPO does not provide a pre-coordinated small fiber neuropathy term in the
    local ontology release; the more specific clinical label is retained in
    preferred_term while mapping to peripheral neuropathy.
  evidence:
  - reference: PMID:41218636
    reference_title: Small Fiber Neuropathy in Sarcoidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An important cause of pain in patients with sarcoidosis is small fiber
      neuropathy (SFN), with an estimated prevalence of 33 to 86%.
    explanation: >-
      This review supports small fiber neuropathy as a frequent
      sarcoidosis-associated peripheral nerve manifestation.
- name: Meningitis
  subtype: Meningeal CNS
  category: Neurologic
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Meningitis
    term:
      id: HP:0001287
      label: Meningitis
  evidence:
  - reference: PMID:28601860
    reference_title: "Characteristics and Long-Term Outcome of Neurosarcoidosis: A Population-Based Study from 1976-2013."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cranial neuropathy was the most common type of neurological disease (5
      patients; 45%) followed by peripheral neuropathy (3 patients; 27%), and
      meningitis (3 patients; 27%).
    explanation: Meningitis was one of the most common neurologic disease types in this population-based cohort.
- name: Hydrocephalus
  subtype: Meningeal CNS
  category: Neurologic
  phenotype_term:
    preferred_term: Hydrocephalus
    term:
      id: HP:0000238
      label: Hydrocephalus
  evidence:
  - reference: PMID:32404428
    reference_title: "Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neurologic manifestations commonly include cranial neuropathies, aseptic
      meningitis, peripheral neuropathy, myelopathy, intraparenchymal mass
      lesions, and hydrocephalus, all of which can lead to significant morbidity
      and mortality.
    explanation: The longitudinal study lists hydrocephalus among common neurologic manifestations.
- name: Optic Neuropathy
  subtype: Cranial Neuropathy
  category: Ophthalmologic
  phenotype_term:
    preferred_term: Optic neuropathy
    term:
      id: HP:0001138
      label: Optic neuropathy
  evidence:
  - reference: PMID:33110001
    reference_title: Neuro-Ophthalmic Manifestations of Sarcoidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neuro-ophthalmic findings included optic neuropathy in 11 (50%);
      proptosis/orbital inflammation in 5 (23%); abducens palsy in 5 (23%);
      trochlear palsy, trigeminal distribution numbness, and bitemporal
      hemianopia in 2 each (9%); and oculomotor palsy, facial palsy, optic
      perineuritis, dorsal midbrain syndrome, central vestibular nystagmus, and
      papilledema in 1 each (5%).
    explanation: The case series directly lists optic neuropathy among neuro-ophthalmic manifestations.
- name: Abducens Palsy
  subtype: Cranial Neuropathy
  category: Neurologic
  phenotype_term:
    preferred_term: Abducens palsy
    term:
      id: HP:0006897
      label: Abducens palsy
  evidence:
  - reference: PMID:33110001
    reference_title: Neuro-Ophthalmic Manifestations of Sarcoidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neuro-ophthalmic findings included optic neuropathy in 11 (50%);
      proptosis/orbital inflammation in 5 (23%); abducens palsy in 5 (23%);
      trochlear palsy, trigeminal distribution numbness, and bitemporal
      hemianopia in 2 each (9%); and oculomotor palsy, facial palsy, optic
      perineuritis, dorsal midbrain syndrome, central vestibular nystagmus, and
      papilledema in 1 each (5%).
    explanation: The neuro-ophthalmology cohort reports abducens palsy as a sarcoidosis-associated manifestation.
- name: Facial Palsy
  subtype: Cranial Neuropathy
  category: Neurologic
  phenotype_term:
    preferred_term: Facial palsy
    term:
      id: HP:0010628
      label: Facial palsy
  evidence:
  - reference: PMID:33110001
    reference_title: Neuro-Ophthalmic Manifestations of Sarcoidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neuro-ophthalmic findings included optic neuropathy in 11 (50%);
      proptosis/orbital inflammation in 5 (23%); abducens palsy in 5 (23%);
      trochlear palsy, trigeminal distribution numbness, and bitemporal
      hemianopia in 2 each (9%); and oculomotor palsy, facial palsy, optic
      perineuritis, dorsal midbrain syndrome, central vestibular nystagmus, and
      papilledema in 1 each (5%).
    explanation: The series lists facial palsy among neuro-ophthalmic manifestations.
- name: Muscle Weakness
  subtype: Meningeal CNS
  category: Neurologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: DOI:10.1038/s41598-023-33631-z
    reference_title: A comprehensive diagnostic approach in suspected neurosarcoidosis
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cranial neuropathies (38%), motor deficit (32%), headache (16%), and
      pituitary dysfunction (12%) were the most common presenting features.
    explanation: Motor deficit was a frequent presenting feature in this diagnostic cohort.
- name: Seizure
  subtype: Meningeal CNS
  category: Neurologic
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: DOI:10.1002/brb3.3443
    reference_title: "Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NS was the initial presentation in 78% of patients, with cranial nerve
      involvement (36%), medullary symptoms (23%), and seizures (21%).
    explanation: Seizures were an occasional initial manifestation in the national multicenter cohort.
- name: Cognitive Impairment
  subtype: Meningeal CNS
  category: Cognitive
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:40769406
    reference_title: "Cognitive impairment in systemic autoimmune and inflammatory diseases: A narrative review focused on ANCA-associated vasculitis, sarcoidosis, Sjögren's syndrome, systemic sclerosis, and Behçet's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Reported prevalence varies widely: ∼30 % in AAV, 0-35 % in sarcoidosis,
      10-80 % in pSS, 8-65 % in SSc, and 30-100 % in BD.
    explanation: >-
      This review supports cognitive impairment as a sarcoidosis-associated
      cognitive phenotype in the occasional frequency range.
- name: Hypopituitarism
  subtype: Hypothalamic-Pituitary
  category: Endocrine
  phenotype_term:
    preferred_term: Hypopituitarism
    term:
      id: HP:0040075
      label: Hypopituitarism
  evidence:
  - reference: PMID:22753675
    reference_title: "Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All but two patients had anterior pituitary dysfunction, 12 patients
      presented with diabetes insipidus.
    explanation: Anterior pituitary dysfunction in hypothalamic-pituitary sarcoidosis maps to hypopituitarism.
- name: Diabetes Insipidus
  subtype: Hypothalamic-Pituitary
  category: Endocrine
  phenotype_term:
    preferred_term: Diabetes insipidus
    term:
      id: HP:0000873
      label: Diabetes insipidus
  evidence:
  - reference: PMID:22753675
    reference_title: "Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All but two patients had anterior pituitary dysfunction, 12 patients
      presented with diabetes insipidus.
    explanation: Diabetes insipidus was a common endocrine presentation in hypothalamic-pituitary sarcoidosis.
histopathology:
- name: Non-caseating granulomatous inflammation
  description: >-
    Non-caseating granulomatous inflammation in neural tissue supports definite
    neurosarcoidosis, while extraneural biopsy evidence of systemic sarcoidosis
    supports probable neurosarcoidosis in the appropriate clinical context.
  diagnostic: true
  context: Neural or extraneural biopsy
  evidence:
  - reference: ORPHA:797
    reference_title: Sarcoidosis
    supports: SUPPORT
    snippet: >-
      A rare multisystemic, autoinflammatory disorder of unknown etiology
      characterized by the formation of immune, non-caseating granulomas in any
      organ(s), leading to variable clinical symptoms and severity.
    explanation: Orphanet identifies non-caseating granulomas as the core sarcoidosis histopathologic process.
  - reference: PMID:30167654
    reference_title: "Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Also emphasized is the need for biopsy, whenever feasible and advisable
      according to clinical context and affected anatomy, of nonneural tissue to
      document the presence of systemic sarcoidosis and support a diagnosis of
      probable neurosarcoidosis or of neural tissue to support a diagnosis of
      definite neurosarcoidosis.
    explanation: >-
      The consensus criteria tie probable and definite neurosarcoidosis
      classification to biopsy confirmation of sarcoidosis.
diagnosis:
- name: MRI assessment
  diagnosis_term:
    preferred_term: magnetic resonance imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  evidence:
  - reference: PMID:33110001
    reference_title: Neuro-Ophthalmic Manifestations of Sarcoidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MRI usually is abnormal, although findings may be nonspecific.
    explanation: MRI is a common diagnostic assessment, while not pathognomonic.
- name: Biopsy confirmation
  diagnosis_term:
    preferred_term: biopsy
    term:
      id: NCIT:C15189
      label: Biopsy Procedure
  evidence:
  - reference: PMID:30167654
    reference_title: "Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Also emphasized is the need for biopsy, whenever feasible and advisable
      according to clinical context and affected anatomy, of nonneural tissue to
      document the presence of systemic sarcoidosis and support a diagnosis of
      probable neurosarcoidosis or of neural tissue to support a diagnosis of
      definite neurosarcoidosis.
    explanation: Biopsy site determines probable versus definite neurosarcoidosis classification.
- name: CSF analysis
  diagnosis_term:
    preferred_term: cerebrospinal fluid analysis
    term:
      id: NCIT:C173272
      label: CSF Analysis
  evidence:
  - reference: PMID:32404428
    reference_title: "Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CSF analysis was performed on 29 patients, but chart documentation of
      these laboratory values was incomplete.
    explanation: CSF analysis is a common inflammatory diagnostic assessment in neurosarcoidosis cohorts.
- name: FDG-PET/CT assessment
  diagnosis_term:
    preferred_term: FDG-positron emission tomography
    term:
      id: NCIT:C103400
      label: FDG-Positron Emission Tomography
  evidence:
  - reference: DOI:10.1038/s41598-023-33631-z
    reference_title: A comprehensive diagnostic approach in suspected neurosarcoidosis
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      FDG-PET/CT was performed in 22 patients (33%) and confirmed systemic
      sarcoidosis in 11.
    explanation: FDG-PET/CT can help identify systemic sarcoidosis and potential extraneural biopsy targets.
biochemical:
- name: CSF Pleocytosis
  presence: INCREASED
  context: >-
    CSF pleocytosis supports CNS inflammation in neurosarcoidosis, especially in
    meningeal, spinal cord, mass-lesion, and some cranial neuropathy
    presentations.
  evidence:
  - reference: PMID:28601860
    reference_title: "Characteristics and Long-Term Outcome of Neurosarcoidosis: A Population-Based Study from 1976-2013."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CSF pleocytosis and high CSF protein level were also observed in the
      patient with intra-medullary spinal cord sarcoidosis, the patient with
      intra-cranial mass lesion and some patients with cranial neuropathy, but
      not in patients with peripheral neuropathy.
    explanation: The cohort links CSF pleocytosis to CNS neurosarcoidosis compartments.
- name: Elevated CSF Protein
  presence: INCREASED
  context: >-
    Elevated CSF protein is a common supportive inflammatory finding, but it is
    not specific and must be interpreted with imaging, biopsy, and exclusion of
    mimics.
  evidence:
  - reference: PMID:32404428
    reference_title: "Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An elevated CSF protein level (>50 mg/dL) was present in 16 of 29 patients
      (55%), and oligoclonal bands were present in 6 of 21 patients (29%).
    explanation: The longitudinal cohort quantifies elevated CSF protein in neurosarcoidosis patients.
- name: Elevated Soluble Interleukin-2 Receptor
  presence: INCREASED
  context: >-
    Serum or CSF soluble interleukin-2 receptor may support inflammatory
    neurosarcoidosis evaluation, especially when differentiating from multiple
    sclerosis or other mimics.
  evidence:
  - reference: DOI:10.3389/fneur.2023.1135392
    reference_title: Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Compared to MS, patients with neurosarcoidosis showed more frequently an
      increased Qalb and CSF lactate levels as well as increased serum and CSF
      levels of sIL-2R, but a lower frequency of intrathecal IgG synthesis and
      positive MRZ reaction.
    explanation: This cohort supports increased soluble IL-2 receptor as part of the inflammatory biomarker profile.
- name: Angiotensin-Converting Enzyme
  presence: INCREASED
  context: >-
    Serum ACE is a traditional supportive sarcoidosis biomarker and CSF ACE has
    limited sensitivity but high specificity in selected probable CNS
    neurosarcoidosis cohorts.
  evidence:
  - reference: PMID:32354749
    reference_title: "Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis: A retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Serum ACE levels were elevated in 51% of patients but in only 14% of those
      with isolated neurosarcoidosis.
    explanation: >-
      This neurosarcoidosis cohort supports serum ACE elevation as a traditional
      but imperfect biomarker.
  - reference: PMID:12405488
    reference_title: CSF-ACE activity in probable CNS neurosarcoidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At this value, the sensitivity and specificity of CSF-ACE activity was 55%
      and 94%, respectively.
    explanation: >-
      This study supports CSF ACE as a high-specificity, limited-sensitivity
      biochemical marker in probable CNS neurosarcoidosis.
- name: Elevated Neurofilament Light Chain
  presence: INCREASED
  context: >-
    Elevated cerebrospinal fluid or plasma neurofilament light chain reflects
    axonal injury and correlates with inflammatory MRI activity in
    neurosarcoidosis.
  evidence:
  - reference: PMID:33672795
    reference_title: Elevated Neurofilament Light Chain in Cerebrospinal Fluid and Plasma Reflect Inflammatory MRI Activity in Neurosarcoidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NFL levels in cerebrospinal fluid and plasma are significantly higher in
      neurosarcoidosis patients compared to extra-neurologic patients and healthy
      controls, and the levels correlate to the extent of inflammation on MRI.
    explanation: This study supports neurofilament light chain as a biomarker of neuroaxonal injury and inflammatory activity.
genetic:
- name: HLA-DRB1
  gene_term:
    preferred_term: HLA-DRB1
    term:
      id: hgnc:4948
      label: HLA-DRB1
  association: HLA class II alleles modify sarcoidosis clinical course and antigen presentation.
  relationship_type: MODIFIER
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:27662826
    reference_title: "Associations between sarcoidosis clinical course and ANXA11 rs1049550 C/T, BTNL2 rs2076530 G/A, and HLA class I and II alleles."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Only the HLA DRB1*03 allele was significantly associated with disease
      resolution (21.2% vs 4.9% for chronic disease; RR = 0.35; P < .01 after
      Bonferroni correction).
    explanation: >-
      Supports HLA-DRB1 allelic variation as a genetic modifier of sarcoidosis
      clinical course.
- name: BTNL2
  gene_term:
    preferred_term: BTNL2
    term:
      id: hgnc:1142
      label: BTNL2
  association: Sarcoidosis susceptibility locus affecting T cell co-stimulation.
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:26164297
    reference_title: "Granuloma genes in sarcoidosis: what is new?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genome-wide genetic screening approaches revealed a number of novel
      susceptibility factors for sarcoidosis, some of which are very likely to
      affect granuloma formation. A splicing variant in the BTNL2 gene had first
      been reported with regards to sarcoidosis by Valentonyte et al. in a
      German study sample 33.
    explanation: >-
      Supports BTNL2 as a sarcoidosis susceptibility gene connected to granuloma
      biology.
- name: ANXA11
  gene_term:
    preferred_term: ANXA11
    term:
      id: hgnc:535
      label: ANXA11
  association: Sarcoidosis susceptibility locus linked to granuloma stability and apoptosis regulation.
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:26164297
    reference_title: "Granuloma genes in sarcoidosis: what is new?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Based on a genome-wide association study (GWAS), variants in the ANXA11
      gene which codes for Annexin 11 were found to be associated with
      sarcoidosis 44 and confirmed in independent populations of German, Czech,
      Portuguese and European and African American origin 37, 45-48.
    explanation: >-
      Supports ANXA11 as a replicated sarcoidosis susceptibility locus.
- name: NOD2
  gene_term:
    preferred_term: NOD2
    term:
      id: hgnc:5331
      label: NOD2
  association: Monogenic sarcoidosis-spectrum granulomatous disease gene in Blau syndrome.
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    NOD2 is not a typical adult neurosarcoidosis susceptibility locus, but
    NOD2-related Blau syndrome is an early-onset sarcoidosis-spectrum
    autoinflammatory granulomatosis relevant to differential genetic context.
  evidence:
  - reference: PMID:32618442
    reference_title: "Blau Syndrome: NOD2-related systemic autoinflammatory granulomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Heterozygous mutations in nucleotide-binding oligomerization domain 2
      (NOD2) were identified as the cause of Blau Syndrome onset.
    explanation: >-
      Supports NOD2 as the causative gene for a sarcoidosis-spectrum
      autoinflammatory granulomatosis.
progression:
- phase: Treatment response and relapse
  notes: >-
    Neurosarcoidosis often initially responds to high-dose glucocorticoids, but
    relapse can occur during dose reduction or discontinuation, requiring
    steroid-sparing immunosuppression or biologic therapy.
  evidence:
  - reference: PMID:28601860
    reference_title: "Characteristics and Long-Term Outcome of Neurosarcoidosis: A Population-Based Study from 1976-2013."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neurosarcoidosis manifestations generally responded well to high-dose
      glucocorticoids in the majority of patients, but relapse was common.
    explanation: This population-based cohort describes the response-relapse pattern.
treatments:
- name: High-dose glucocorticoids
  description: >-
    High-dose glucocorticoids such as prednisone or intravenous
    methylprednisolone are commonly used as initial therapy, but long-term
    toxicity and relapse during taper often necessitate steroid-sparing agents.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: corticosteroid
      term:
        id: NCIT:C211
        label: Therapeutic Corticosteroid
    - preferred_term: prednisone
      term:
        id: CHEBI:8382
        label: prednisone
  target_mechanisms:
  - target: Nervous System Granulomatous Inflammation
    treatment_effect: INHIBITS
    description: Glucocorticoids suppress the granulomatous inflammatory process.
    evidence:
    - reference: PMID:28601860
      reference_title: "Characteristics and Long-Term Outcome of Neurosarcoidosis: A Population-Based Study from 1976-2013."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Almost all patients had a good response to initial treatment with high-dose
        glucocorticoids, often initially 1 gram methylprednisolone daily for 3 to
        5 days, or prednisone, 1 mg/kg body weight as initial dose.
      explanation: Clinical response to high-dose glucocorticoids supports inhibition of active inflammatory disease.
  evidence:
  - reference: PMID:28601860
    reference_title: "Characteristics and Long-Term Outcome of Neurosarcoidosis: A Population-Based Study from 1976-2013."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients received high-dose glucocorticoids as initial treatment and
      almost all responded to this therapy.
    explanation: Supports glucocorticoids as common initial treatment with frequent initial response.
- name: Conventional steroid-sparing immunosuppression
  description: >-
    Methotrexate, azathioprine, mycophenolate mofetil, and related
    immunosuppressants are used when glucocorticoid taper fails or prolonged
    steroid exposure is undesirable.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: methotrexate
      term:
        id: CHEBI:44185
        label: methotrexate
    - preferred_term: azathioprine
      term:
        id: CHEBI:2948
        label: azathioprine
    - preferred_term: immunosuppressant
      term:
        id: NCIT:C574
        label: Immunosuppressant
  target_mechanisms:
  - target: Nervous System Granulomatous Inflammation
    treatment_effect: INHIBITS
    description: Steroid-sparing immunosuppressants reduce adaptive immune activity sustaining granulomatous inflammation.
    evidence:
    - reference: PMID:28601860
      reference_title: "Characteristics and Long-Term Outcome of Neurosarcoidosis: A Population-Based Study from 1976-2013."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Several disease-modifying anti-rheumatic disease drugs (DMARDs), including
        methotrexate, mycophenolate mofetil, hydroxychloroquine and azathioprine,
        were used in this cohort as glucocorticoid-sparing agents after failure of
        glucocorticoids taper.
      explanation: Steroid-sparing DMARD use supports immunosuppression as a treatment mechanism.
  evidence:
  - reference: PMID:28601860
    reference_title: "Characteristics and Long-Term Outcome of Neurosarcoidosis: A Population-Based Study from 1976-2013."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Several disease-modifying anti-rheumatic disease drugs (DMARDs), including
      methotrexate, mycophenolate mofetil, hydroxychloroquine and azathioprine,
      were used in this cohort as glucocorticoid-sparing agents after failure of
      glucocorticoids taper.
    explanation: The cohort documents conventional immunosuppressants used as steroid-sparing agents.
- name: Infliximab
  description: >-
    TNF-alpha blockade with infliximab is used for refractory or severe
    neurosarcoidosis and has cohort evidence for stabilization or improvement.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: infliximab
      term:
        id: NCIT:C1789
        label: Infliximab
  target_mechanisms:
  - target: Nervous System Granulomatous Inflammation
    treatment_effect: INHIBITS
    description: TNF-alpha blockade targets a cytokine axis required for granulomatous inflammation.
    evidence:
    - reference: PMID:32404428
      reference_title: "Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This robust response is because of TNFα's critical role in the granuloma
        formation and supported by the high recurrence rate seen after stopping
        the medication.
      explanation: The cohort explicitly relates infliximab response to TNF-alpha's role in granuloma biology.
  evidence:
  - reference: PMID:32404428
    reference_title: "Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Infliximab was the most effective therapy, with 87% of patients remaining
      stable or improving on infliximab.
    explanation: The longitudinal cohort supports infliximab effectiveness in neurosarcoidosis.
  - reference: PMID:28260120
    reference_title: Long-term outcomes of refractory neurosarcoidosis treated with infliximab.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At 6 months after initiation of infliximab, six patients obtained complete
      remission (33%), ten attained partial remission (56%), and two had stable
      disease (11%).
    explanation: A refractory neurosarcoidosis cohort reports remission or stability after infliximab.
  - reference: DOI:10.1002/acn3.51968
    reference_title: "Infliximab in neurosarcoidosis: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Infliximab demonstrated potential improvement in clinical outcomes for
      patients with refractory neurosarcoidosis and showed potential for reducing
      the dosage of concurrent corticosteroids.
    explanation: The systematic review provides pooled outcome support for infliximab in neurosarcoidosis.
- name: Adalimumab
  description: >-
    Adalimumab is an alternative TNF-alpha inhibitor with limited case-series
    evidence for clinical and radiographic response in neurosarcoidosis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: adalimumab
      term:
        id: NCIT:C65216
        label: Adalimumab
  target_mechanisms:
  - target: Nervous System Granulomatous Inflammation
    treatment_effect: INHIBITS
    description: TNF-alpha blockade targets granulomatous inflammatory signaling.
    evidence:
    - reference: PMID:38640580
      reference_title: "Adalimumab as treatment for neurosarcoidosis: A case series."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We discovered ten neurosarcoidosis patients who were on an alternative
        TNA-alpha inhibitor, adalimumab.
      explanation: The case series identifies adalimumab as an alternative TNF-alpha inhibitor used in neurosarcoidosis.
  evidence:
  - reference: PMID:38640580
    reference_title: "Adalimumab as treatment for neurosarcoidosis: A case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eight patients had a positive response clinically and radiographically to
      adalimumab.
    explanation: A small case series reports clinical and radiographic response to adalimumab.
clinical_trials:
- name: NCT02920710
  phase: PHASE_IV
  status: WITHDRAWN
  description: ACTHAR gel study for severe central nervous system sarcoidosis.
  evidence:
  - reference: clinicaltrials:NCT02920710
    reference_title: ACTHAR Therapy for Central Nervous System Sarcoidosis
    supports: SUPPORT
    snippet: >-
      This study aims to provide evidence for effectiveness of ACTHAR gel in CNS
      sarcoidosis, and provide information about its safety and tolerability
    explanation: ClinicalTrials.gov describes an interventional ACTHAR study specific to CNS sarcoidosis.
- name: NCT04911348
  status: UNKNOWN
  description: Multicenter retrospective study of initial presentation and disease course in neurosarcoidosis.
  evidence:
  - reference: clinicaltrials:NCT04911348
    reference_title: "Neurosarcoidosis : Initial Presentation and Disease Course, a Multicenter Retrospective Study"
    supports: SUPPORT
    snippet: >-
      Using retrospective data from patients diagnosed with neurosarcoidosis in
      three French referral centers for neuro-inflammation, the investigators aim
      to determine patterns of disease course, according to the initial
      presentation and the treatments used.
    explanation: The trial registry describes a neurosarcoidosis-specific disease-course study.
references:
- reference: DOI:10.1001/jamaneurol.2018.2295
  title: Definition and Consensus Diagnostic Criteria for Neurosarcoidosis
  found_in:
  - Neurosarcoidosis-deep-research-falcon.md
- reference: DOI:10.1002/acn3.51968
  title: 'Infliximab in neurosarcoidosis: a systematic review and meta‐analysis'
  found_in:
  - Neurosarcoidosis-deep-research-falcon.md
  findings:
  - statement: To evaluate the clinical outcomes and relapse rates in neurosarcoidosis patients administered infliximab.MethodsA systematic review was conducted using the MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases.
    supporting_text: To evaluate the clinical outcomes and relapse rates in neurosarcoidosis patients administered infliximab.MethodsA systematic review was conducted using the MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases.
    evidence:
    - reference: DOI:10.1002/acn3.51968
      reference_title: 'Infliximab in neurosarcoidosis: a systematic review and meta‐analysis'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: To evaluate the clinical outcomes and relapse rates in neurosarcoidosis patients administered infliximab.MethodsA systematic review was conducted using the MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases.
      explanation: Deep research cited this publication as relevant literature for Neurosarcoidosis.
- reference: DOI:10.1002/brb3.3443
  title: 'Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort'
  found_in:
  - Neurosarcoidosis-deep-research-falcon.md
  findings:
  - statement: Neurosarcoidosis (NS) is a systemic inflammatory granulomatous disease affecting of patients with sarcoidosis.
    supporting_text: Neurosarcoidosis (NS) is a systemic inflammatory granulomatous disease affecting of patients with sarcoidosis.
    evidence:
    - reference: DOI:10.1002/brb3.3443
      reference_title: 'Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Neurosarcoidosis (NS) is a systemic inflammatory granulomatous disease affecting of patients with sarcoidosis.
      explanation: Deep research cited this publication as relevant literature for Neurosarcoidosis.
- reference: DOI:10.1038/s41598-021-92967-6
  title: Clinical characterization and outcomes of 85 patients with neurosarcoidosis
  found_in:
  - Neurosarcoidosis-deep-research-falcon.md
  - Neurosarcoidosis-deep-research-openscientist.md
  findings:
  - statement: To analyze the frequency and clinical phenotype of neurosarcoidosis (NS) in one of the largest nationwide cohorts of patients with sarcoidosis reported from southern Europe.
    supporting_text: To analyze the frequency and clinical phenotype of neurosarcoidosis (NS) in one of the largest nationwide cohorts of patients with sarcoidosis reported from southern Europe.
    evidence:
    - reference: DOI:10.1038/s41598-021-92967-6
      reference_title: Clinical characterization and outcomes of 85 patients with neurosarcoidosis
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: To analyze the frequency and clinical phenotype of neurosarcoidosis (NS) in one of the largest nationwide cohorts of patients with sarcoidosis reported from southern Europe.
      explanation: Deep research cited this publication as relevant literature for Neurosarcoidosis.
- reference: DOI:10.1038/s41598-023-33631-z
  title: A comprehensive diagnostic approach in suspected neurosarcoidosis
  found_in:
  - Neurosarcoidosis-deep-research-falcon.md
  findings:
  - statement: Neurosarcoidosis presents a diagnostic challenge in clinical settings, as it has no pathognomonic symptoms or signs and a wide range of differential diagnoses.
    supporting_text: Neurosarcoidosis presents a diagnostic challenge in clinical settings, as it has no pathognomonic symptoms or signs and a wide range of differential diagnoses.
    evidence:
    - reference: DOI:10.1038/s41598-023-33631-z
      reference_title: A comprehensive diagnostic approach in suspected neurosarcoidosis
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Neurosarcoidosis presents a diagnostic challenge in clinical settings, as it has no pathognomonic symptoms or signs and a wide range of differential diagnoses.
      explanation: Deep research cited this publication as relevant literature for Neurosarcoidosis.
- reference: DOI:10.1080/14737175.2022.2108705
  title: 'Neurosarcoidosis: an update on diagnosis and therapy'
  found_in:
  - Neurosarcoidosis-deep-research-falcon.md
- reference: DOI:10.1177/11795735241274186
  title: 'Diagnostic value of soluble Interleukin-2 receptor in patients suffering neurosarcoidosis: A systematic review'
  found_in:
  - Neurosarcoidosis-deep-research-falcon.md
  - Neurosarcoidosis-deep-research-openscientist.md
  findings:
  - statement: Neurosarcoidosis is an inflammatory granulomatous disease.
    supporting_text: Neurosarcoidosis is an inflammatory granulomatous disease.
    evidence:
    - reference: DOI:10.1177/11795735241274186
      reference_title: 'Diagnostic value of soluble Interleukin-2 receptor in patients suffering neurosarcoidosis: A systematic review'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Neurosarcoidosis is an inflammatory granulomatous disease.
      explanation: Deep research cited this publication as relevant literature for Neurosarcoidosis.
- reference: DOI:10.3389/fneur.2022.970168
  title: 'Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: A mono-centric retrospective study and literature review'
  found_in:
  - Neurosarcoidosis-deep-research-falcon.md
  findings:
  - statement: 'Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: A mono-centric retrospective study and literature review'
    supporting_text: Neurosarcoidosis is a rare granulomatous disorder, and treatment guidelines are mainly based on retrospective studies.Materials and methodsThis retrospective study was performed to provide a detailed description of the clinical characteristics and treatment outcomes of patients with neurosarcoidosis followed at Cliniques Universitaires Saint Luc in Belgium.
    evidence:
    - reference: DOI:10.3389/fneur.2022.970168
      reference_title: 'Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: A mono-centric retrospective study and literature review'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Neurosarcoidosis is a rare granulomatous disorder, and treatment guidelines are mainly based on retrospective studies.Materials and methodsThis retrospective study was performed to provide a detailed description of the clinical characteristics and treatment outcomes of patients with neurosarcoidosis followed at Cliniques Universitaires Saint Luc in Belgium.
      explanation: Deep research cited this publication as relevant literature for Neurosarcoidosis.
- reference: DOI:10.3389/fneur.2023.1135392
  title: Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction
  found_in:
  - Neurosarcoidosis-deep-research-falcon.md
  - Neurosarcoidosis-deep-research-openscientist.md
  findings:
  - statement: Neurosarcodosis is one of the most frequent differential diagnoses of multiple sclerosis (MS) and requires central nervous system (CNS) biopsy to establish definite diagnosis according to the latest consensus diagnostic criteria.
    supporting_text: Neurosarcodosis is one of the most frequent differential diagnoses of multiple sclerosis (MS) and requires central nervous system (CNS) biopsy to establish definite diagnosis according to the latest consensus diagnostic criteria.
    evidence:
    - reference: DOI:10.3389/fneur.2023.1135392
      reference_title: Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Neurosarcodosis is one of the most frequent differential diagnoses of multiple sclerosis (MS) and requires central nervous system (CNS) biopsy to establish definite diagnosis according to the latest consensus diagnostic criteria.
      explanation: Deep research cited this publication as relevant literature for Neurosarcoidosis.
- reference: DOI:10.3390/life14010069
  title: 'Neurosarcoidosis: The Presentation, Diagnosis and Treatment Review of Two Cases'
  found_in:
  - Neurosarcoidosis-deep-research-falcon.md
  findings:
  - statement: Sarcoidosis is a chronic granulomatous disease of unknown cause characterized by the presence of non-caseating granulomas.
    supporting_text: Sarcoidosis is a chronic granulomatous disease of unknown cause characterized by the presence of non-caseating granulomas.
    evidence:
    - reference: DOI:10.3390/life14010069
      reference_title: 'Neurosarcoidosis: The Presentation, Diagnosis and Treatment Review of Two Cases'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Sarcoidosis is a chronic granulomatous disease of unknown cause characterized by the presence of non-caseating granulomas.
      explanation: Deep research cited this publication as relevant literature for Neurosarcoidosis.
- reference: DOI:10.7759/cureus.69208
  title: 'Neurosarcoidosis: Current Perspectives on Diagnosis, Management, and Future Directions'
  found_in:
  - Neurosarcoidosis-deep-research-falcon.md
  - Neurosarcoidosis-deep-research-openscientist.md
- reference: PMID:10207931
  title: The pitfall of silent neurosarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:11158062
  title: Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:12405488
  title: CSF-ACE activity in probable CNS neurosarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:15347561
  title: 'A case control etiologic study of sarcoidosis: environmental and occupational risk factors.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:18977817
  title: 'Neurosarcoidosis: a study of 30 new cases.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:19755199
  title: Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:22529133
  title: Mycobacterium DNA detection in liver and skin of a horse with generalized sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:22753675
  title: 'Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:22952805
  title: Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:23331701
  title: 'Equine sarcoidosis: clinical signs, diagnosis, treatment and outcome of 22 cases.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:23685039
  title: 'Isolated paediatric neurosarcoidosis presenting as epilepsia partialis continua: a case report and review of literature.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:24242359
  title: Epigenetics in immune-mediated pulmonary diseases.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:24663488
  title: Admixture fine-mapping in African Americans implicates XAF1 as a possible sarcoidosis risk gene.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:26051272
  title: Identification of Immune-Relevant Factors Conferring Sarcoidosis Genetic Risk.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:26164297
  title: 'Granuloma genes in sarcoidosis: what is new?'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:27662826
  title: Associations between sarcoidosis clinical course and ANXA11 rs1049550 C/T, BTNL2 rs2076530 G/A, and HLA class I and II alleles.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:29030454
  title: 'Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:29052709
  title: Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:29066387
  title: Clinical Course of Sarcoidosis in World Trade Center-Exposed Firefighters.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:29239767
  title: 'Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:29416296
  title: Association of genetic variants in RAB23 and ANXA11 with uveitis in sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:30430892
  title: A case of fatal invasive aspergillosis in a patient with neurosarcoidosis treated with infliximab.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:30587386
  title: 'Clinical epidemiology of familial sarcoidosis: A systematic literature review.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:30739183
  title: 'Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:30944672
  title: 'Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:31101981
  title: 'Sarcoidosis and Work Participation: The Need to Develop a Disease-Specific Core Set for Assessment of Work Ability.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:31672631
  title: Combined application of angiotensin converting enzyme and chitotriosidase analysis improves the laboratory diagnosis of sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:31855785
  title: 'Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: A randomized controlled trial.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:32114588
  title: The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:32256501
  title: Adaptive Immunity in Pulmonary Sarcoidosis and Chronic Beryllium Disease.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:32354749
  title: 'Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis: A retrospective study.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:32618442
  title: 'Blau Syndrome: NOD2-related systemic autoinflammatory granulomatosis.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:32676081
  title: Environmental Risk Factors for Sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:32703543
  title: 'Retrospective, dual-centre review of imaging findings in neurosarcoidosis at presentation: prevalence and imaging sub-types.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:32718952
  title: Infliximab treatment in pathology-confirmed neurosarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:32771711
  title: The effect of race on clinical presentation and outcomes in neurosarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:32826979
  title: Genetic control of CCL24, POR, and IL23R contributes to the pathogenesis of sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:33077072
  title: Equine Idiopathic Systemic Granulomatous Disease With Manifestation in the Cerebellum Associated With Equid Gammaherpesvirus 2.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:33672795
  title: Elevated Neurofilament Light Chain in Cerebrospinal Fluid and Plasma Reflect Inflammatory MRI Activity in Neurosarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:33769630
  title: Diabetes insipidus secondary to sellar/parasellar lesions.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:34168064
  title: Epigenetics and sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:34607912
  title: 'Neurosarcoidosis: Pathophysiology, Diagnosis, and Treatment.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:35145013
  title: 'Prognostic Factors and Treatment Efficacy in Spinal Cord Sarcoidosis: An Observational Cohort With Long-term Follow-up.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:35510170
  title: 'Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:35997361
  title: Relevance of Medullary Vein Sign in Neurosarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:36427515
  title: 'Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:36858037
  title: Minor Salivary Gland Biopsy for the Diagnosis of Neurosarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:37250650
  title: Sex differences in the genetics of sarcoidosis across European and African ancestry populations.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:37399103
  title: Genome-wide association study identifies multiple HLA loci for sarcoidosis susceptibility.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:37690784
  title: 'High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial).'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:38181319
  title: 'Cardiac Involvement in Neurosarcoidosis: A Single-Center Investigation.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:38268056
  title: 'Reevaluating the relevance of (18)F-FDG PET findings for diagnosis of neurosarcoidosis: a case series.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:38353578
  title: Aberrant Lipid Metabolism in Macrophages Is Associated with Granuloma Formation in Sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:38385142
  title: Immune mapping of human tuberculosis and sarcoidosis lung granulomas.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:38640580
  title: 'Adalimumab as treatment for neurosarcoidosis: A case series.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:38852524
  title: Anti-TL1A monoclonal antibody modulates the dysregulation of Th1/Th17 cells and attenuates granuloma formation in sarcoidosis by inhibiting the PI3K/AKT signaling pathway.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:38864562
  title: Development of a Mouse Cardiac Sarcoidosis Model Using Carbon Nanotubes.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:39209060
  title: Sarcoidosis and Emergency Hospitalization.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:39615612
  title: Generalized sarcoidosis associated with hypertrophic osteopathy in a Standardbred racehorse.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:39826790
  title: Jiawei Yanghe Decoction alleviates pulmonary sarcoidosis by upregulating NR1D1/2 and suppressing Th17 cells.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:39896662
  title: Single Cell Transcriptome Signatures of Sarcoidosis in Lung Immune Cell Populations.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:39951973
  title: Exploring the anti-inflammatory effects of Radix Curcumae essential oil in pulmonary sarcoidosis via the TLR4/MyD88/NF-κB pathway.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:40023555
  title: Predictors of visual outcome in optic neuropathy of sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:40668560
  title: MALDI-MSI reveals shared lipid signatures in sarcoid-like granulomas of mice and in a human case.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:40702280
  title: 'Comparing the efficacy and safety of cyclophosphamide, infliximab and methotrexate in neurosarcoidosis: a multicenter retrospective study.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:40769406
  title: "Cognitive impairment in systemic autoimmune and inflammatory diseases: A narrative review focused on ANCA-associated vasculitis, sarcoidosis, Sjögren's syndrome, systemic sclerosis, and Behçet's disease."
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:41015397
  title: Comparison of the effects of one-legged and two-legged exercise training on exercise capacity and fatigue in patients with sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:41054684
  title: A Fulminant Case of Refractory Sarcoidosis Triggered by Infliximab-Neutralizing Antibodies.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:41213628
  title: 'Biomarkers in Sarcoidosis: From Traditional Markers to Precision Medicine.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:41218636
  title: Small Fiber Neuropathy in Sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:41316274
  title: The interplay between M2-like macrophages and Th17.1 cells promotes the progression of early-stage sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:41371265
  title: 'Neurosarcoidosis in Critical Care, Internal, and Pulmonary Medicine: A Practical Approach.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:41380938
  title: 'TEAM Sarcoidosis: Creating a Multidisciplinary Care Team for Complex Clinical Management.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:41429672
  title: Neuro-Ophthalmic Manifestations of Neurosarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:41459541
  title: Clinical updates of JAK inhibitors in cutaneous granulomatous diseases.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:41476976
  title: βc receptor antagonism mitigates sarcoidosis granuloma formation by targeting inflammatory signals and aberrant lipid metabolism.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:41651390
  title: 'Sarcoidosis: Disease mechanisms, diagnostic pathway and treatment.'
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:42084847
  title: Extracellular vimentin promotes neutrophil-dominant granulomatous inflammation in progressive pulmonary sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:15925652
  title: Sarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:30167654
  title: "Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group."
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:32404428
  title: "Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system."
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:34215779
  title: Clinical characterization and outcomes of 85 patients with neurosarcoidosis.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:37034091
  title: Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction.
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:39193252
  title: "Diagnostic value of soluble Interleukin-2 receptor in patients suffering neurosarcoidosis: A systematic review."
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
- reference: PMID:39398844
  title: "Neurosarcoidosis: Current Perspectives on Diagnosis, Management, and Future Directions."
  found_in:
  - Neurosarcoidosis-deep-research-openscientist.md
  findings: []
📚

References & Deep Research

References

96
DOI:10.1001/jamaneurol.2018.2295
Definition and Consensus Diagnostic Criteria for Neurosarcoidosis
No top-level findings curated for this source.
DOI:10.1002/acn3.51968
Infliximab in neurosarcoidosis: a systematic review and meta‐analysis
1 finding
To evaluate the clinical outcomes and relapse rates in neurosarcoidosis patients administered infliximab.MethodsA systematic review was conducted using the MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases.
"To evaluate the clinical outcomes and relapse rates in neurosarcoidosis patients administered infliximab.MethodsA systematic review was conducted using the MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases."
Show evidence (1 reference)
DOI:10.1002/acn3.51968 SUPPORT Human Clinical
"To evaluate the clinical outcomes and relapse rates in neurosarcoidosis patients administered infliximab.MethodsA systematic review was conducted using the MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases."
Deep research cited this publication as relevant literature for Neurosarcoidosis.
DOI:10.1002/brb3.3443
Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort
1 finding
Neurosarcoidosis (NS) is a systemic inflammatory granulomatous disease affecting of patients with sarcoidosis.
"Neurosarcoidosis (NS) is a systemic inflammatory granulomatous disease affecting of patients with sarcoidosis."
Show evidence (1 reference)
DOI:10.1002/brb3.3443 SUPPORT Human Clinical
"Neurosarcoidosis (NS) is a systemic inflammatory granulomatous disease affecting of patients with sarcoidosis."
Deep research cited this publication as relevant literature for Neurosarcoidosis.
DOI:10.1038/s41598-021-92967-6
Clinical characterization and outcomes of 85 patients with neurosarcoidosis
1 finding
To analyze the frequency and clinical phenotype of neurosarcoidosis (NS) in one of the largest nationwide cohorts of patients with sarcoidosis reported from southern Europe.
"To analyze the frequency and clinical phenotype of neurosarcoidosis (NS) in one of the largest nationwide cohorts of patients with sarcoidosis reported from southern Europe."
Show evidence (1 reference)
DOI:10.1038/s41598-021-92967-6 SUPPORT Human Clinical
"To analyze the frequency and clinical phenotype of neurosarcoidosis (NS) in one of the largest nationwide cohorts of patients with sarcoidosis reported from southern Europe."
Deep research cited this publication as relevant literature for Neurosarcoidosis.
DOI:10.1038/s41598-023-33631-z
A comprehensive diagnostic approach in suspected neurosarcoidosis
1 finding
Neurosarcoidosis presents a diagnostic challenge in clinical settings, as it has no pathognomonic symptoms or signs and a wide range of differential diagnoses.
"Neurosarcoidosis presents a diagnostic challenge in clinical settings, as it has no pathognomonic symptoms or signs and a wide range of differential diagnoses."
Show evidence (1 reference)
DOI:10.1038/s41598-023-33631-z SUPPORT Human Clinical
"Neurosarcoidosis presents a diagnostic challenge in clinical settings, as it has no pathognomonic symptoms or signs and a wide range of differential diagnoses."
Deep research cited this publication as relevant literature for Neurosarcoidosis.
DOI:10.1080/14737175.2022.2108705
Neurosarcoidosis: an update on diagnosis and therapy
No top-level findings curated for this source.
DOI:10.1177/11795735241274186
Diagnostic value of soluble Interleukin-2 receptor in patients suffering neurosarcoidosis: A systematic review
1 finding
Neurosarcoidosis is an inflammatory granulomatous disease.
"Neurosarcoidosis is an inflammatory granulomatous disease."
Show evidence (1 reference)
DOI:10.1177/11795735241274186 SUPPORT Human Clinical
"Neurosarcoidosis is an inflammatory granulomatous disease."
Deep research cited this publication as relevant literature for Neurosarcoidosis.
DOI:10.3389/fneur.2022.970168
Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: A mono-centric retrospective study and literature review
1 finding
Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: A mono-centric retrospective study and literature review
"Neurosarcoidosis is a rare granulomatous disorder, and treatment guidelines are mainly based on retrospective studies.Materials and methodsThis retrospective study was performed to provide a detailed description of the clinical characteristics and treatment outcomes of patients with..."
Show evidence (1 reference)
DOI:10.3389/fneur.2022.970168 SUPPORT Human Clinical
"Neurosarcoidosis is a rare granulomatous disorder, and treatment guidelines are mainly based on retrospective studies.Materials and methodsThis retrospective study was performed to provide a detailed description of the clinical characteristics and treatment outcomes of patients with..."
Deep research cited this publication as relevant literature for Neurosarcoidosis.
DOI:10.3389/fneur.2023.1135392
Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction
1 finding
Neurosarcodosis is one of the most frequent differential diagnoses of multiple sclerosis (MS) and requires central nervous system (CNS) biopsy to establish definite diagnosis according to the latest consensus diagnostic criteria.
"Neurosarcodosis is one of the most frequent differential diagnoses of multiple sclerosis (MS) and requires central nervous system (CNS) biopsy to establish definite diagnosis according to the latest consensus diagnostic criteria."
Show evidence (1 reference)
DOI:10.3389/fneur.2023.1135392 SUPPORT Human Clinical
"Neurosarcodosis is one of the most frequent differential diagnoses of multiple sclerosis (MS) and requires central nervous system (CNS) biopsy to establish definite diagnosis according to the latest consensus diagnostic criteria."
Deep research cited this publication as relevant literature for Neurosarcoidosis.
DOI:10.3390/life14010069
Neurosarcoidosis: The Presentation, Diagnosis and Treatment Review of Two Cases
1 finding
Sarcoidosis is a chronic granulomatous disease of unknown cause characterized by the presence of non-caseating granulomas.
"Sarcoidosis is a chronic granulomatous disease of unknown cause characterized by the presence of non-caseating granulomas."
Show evidence (1 reference)
DOI:10.3390/life14010069 SUPPORT Human Clinical
"Sarcoidosis is a chronic granulomatous disease of unknown cause characterized by the presence of non-caseating granulomas."
Deep research cited this publication as relevant literature for Neurosarcoidosis.
DOI:10.7759/cureus.69208
Neurosarcoidosis: Current Perspectives on Diagnosis, Management, and Future Directions
No top-level findings curated for this source.
PMID:10207931
The pitfall of silent neurosarcoidosis.
No top-level findings curated for this source.
PMID:11158062
Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase.
No top-level findings curated for this source.
PMID:12405488
CSF-ACE activity in probable CNS neurosarcoidosis.
No top-level findings curated for this source.
PMID:15347561
A case control etiologic study of sarcoidosis: environmental and occupational risk factors.
No top-level findings curated for this source.
PMID:18977817
Neurosarcoidosis: a study of 30 new cases.
No top-level findings curated for this source.
PMID:19755199
Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis.
No top-level findings curated for this source.
PMID:22529133
Mycobacterium DNA detection in liver and skin of a horse with generalized sarcoidosis.
No top-level findings curated for this source.
PMID:22753675
Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients.
No top-level findings curated for this source.
PMID:22952805
Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility.
No top-level findings curated for this source.
PMID:23331701
Equine sarcoidosis: clinical signs, diagnosis, treatment and outcome of 22 cases.
No top-level findings curated for this source.
PMID:23685039
Isolated paediatric neurosarcoidosis presenting as epilepsia partialis continua: a case report and review of literature.
No top-level findings curated for this source.
PMID:24242359
Epigenetics in immune-mediated pulmonary diseases.
No top-level findings curated for this source.
PMID:24663488
Admixture fine-mapping in African Americans implicates XAF1 as a possible sarcoidosis risk gene.
No top-level findings curated for this source.
PMID:26051272
Identification of Immune-Relevant Factors Conferring Sarcoidosis Genetic Risk.
No top-level findings curated for this source.
PMID:26164297
Granuloma genes in sarcoidosis: what is new?
No top-level findings curated for this source.
PMID:27662826
Associations between sarcoidosis clinical course and ANXA11 rs1049550 C/T, BTNL2 rs2076530 G/A, and HLA class I and II alleles.
No top-level findings curated for this source.
PMID:29030454
Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.
No top-level findings curated for this source.
PMID:29052709
Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis.
No top-level findings curated for this source.
PMID:29066387
Clinical Course of Sarcoidosis in World Trade Center-Exposed Firefighters.
No top-level findings curated for this source.
PMID:29239767
Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study.
No top-level findings curated for this source.
PMID:29416296
Association of genetic variants in RAB23 and ANXA11 with uveitis in sarcoidosis.
No top-level findings curated for this source.
PMID:30430892
A case of fatal invasive aspergillosis in a patient with neurosarcoidosis treated with infliximab.
No top-level findings curated for this source.
PMID:30587386
Clinical epidemiology of familial sarcoidosis: A systematic literature review.
No top-level findings curated for this source.
PMID:30739183
Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment.
No top-level findings curated for this source.
PMID:30944672
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6.
No top-level findings curated for this source.
PMID:31101981
Sarcoidosis and Work Participation: The Need to Develop a Disease-Specific Core Set for Assessment of Work Ability.
No top-level findings curated for this source.
PMID:31672631
Combined application of angiotensin converting enzyme and chitotriosidase analysis improves the laboratory diagnosis of sarcoidosis.
No top-level findings curated for this source.
PMID:31855785
Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: A randomized controlled trial.
No top-level findings curated for this source.
PMID:32114588
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients.
No top-level findings curated for this source.
PMID:32256501
Adaptive Immunity in Pulmonary Sarcoidosis and Chronic Beryllium Disease.
No top-level findings curated for this source.
PMID:32354749
Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis: A retrospective study.
No top-level findings curated for this source.
PMID:32618442
Blau Syndrome: NOD2-related systemic autoinflammatory granulomatosis.
No top-level findings curated for this source.
PMID:32676081
Environmental Risk Factors for Sarcoidosis.
No top-level findings curated for this source.
PMID:32703543
Retrospective, dual-centre review of imaging findings in neurosarcoidosis at presentation: prevalence and imaging sub-types.
No top-level findings curated for this source.
PMID:32718952
Infliximab treatment in pathology-confirmed neurosarcoidosis.
No top-level findings curated for this source.
PMID:32771711
The effect of race on clinical presentation and outcomes in neurosarcoidosis.
No top-level findings curated for this source.
PMID:32826979
Genetic control of CCL24, POR, and IL23R contributes to the pathogenesis of sarcoidosis.
No top-level findings curated for this source.
PMID:33077072
Equine Idiopathic Systemic Granulomatous Disease With Manifestation in the Cerebellum Associated With Equid Gammaherpesvirus 2.
No top-level findings curated for this source.
PMID:33672795
Elevated Neurofilament Light Chain in Cerebrospinal Fluid and Plasma Reflect Inflammatory MRI Activity in Neurosarcoidosis.
No top-level findings curated for this source.
PMID:33769630
Diabetes insipidus secondary to sellar/parasellar lesions.
No top-level findings curated for this source.
PMID:34168064
Epigenetics and sarcoidosis.
No top-level findings curated for this source.
PMID:34607912
Neurosarcoidosis: Pathophysiology, Diagnosis, and Treatment.
No top-level findings curated for this source.
PMID:35145013
Prognostic Factors and Treatment Efficacy in Spinal Cord Sarcoidosis: An Observational Cohort With Long-term Follow-up.
No top-level findings curated for this source.
PMID:35510170
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review.
No top-level findings curated for this source.
PMID:35997361
Relevance of Medullary Vein Sign in Neurosarcoidosis.
No top-level findings curated for this source.
PMID:36427515
Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial.
No top-level findings curated for this source.
PMID:36858037
Minor Salivary Gland Biopsy for the Diagnosis of Neurosarcoidosis.
No top-level findings curated for this source.
PMID:37250650
Sex differences in the genetics of sarcoidosis across European and African ancestry populations.
No top-level findings curated for this source.
PMID:37399103
Genome-wide association study identifies multiple HLA loci for sarcoidosis susceptibility.
No top-level findings curated for this source.
PMID:37690784
High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial).
No top-level findings curated for this source.
PMID:38181319
Cardiac Involvement in Neurosarcoidosis: A Single-Center Investigation.
No top-level findings curated for this source.
PMID:38268056
Reevaluating the relevance of (18)F-FDG PET findings for diagnosis of neurosarcoidosis: a case series.
No top-level findings curated for this source.
PMID:38353578
Aberrant Lipid Metabolism in Macrophages Is Associated with Granuloma Formation in Sarcoidosis.
No top-level findings curated for this source.
PMID:38385142
Immune mapping of human tuberculosis and sarcoidosis lung granulomas.
No top-level findings curated for this source.
PMID:38640580
Adalimumab as treatment for neurosarcoidosis: A case series.
No top-level findings curated for this source.
PMID:38852524
Anti-TL1A monoclonal antibody modulates the dysregulation of Th1/Th17 cells and attenuates granuloma formation in sarcoidosis by inhibiting the PI3K/AKT signaling pathway.
No top-level findings curated for this source.
PMID:38864562
Development of a Mouse Cardiac Sarcoidosis Model Using Carbon Nanotubes.
No top-level findings curated for this source.
PMID:39209060
Sarcoidosis and Emergency Hospitalization.
No top-level findings curated for this source.
PMID:39615612
Generalized sarcoidosis associated with hypertrophic osteopathy in a Standardbred racehorse.
No top-level findings curated for this source.
PMID:39826790
Jiawei Yanghe Decoction alleviates pulmonary sarcoidosis by upregulating NR1D1/2 and suppressing Th17 cells.
No top-level findings curated for this source.
PMID:39896662
Single Cell Transcriptome Signatures of Sarcoidosis in Lung Immune Cell Populations.
No top-level findings curated for this source.
PMID:39951973
Exploring the anti-inflammatory effects of Radix Curcumae essential oil in pulmonary sarcoidosis via the TLR4/MyD88/NF-κB pathway.
No top-level findings curated for this source.
PMID:40023555
Predictors of visual outcome in optic neuropathy of sarcoidosis.
No top-level findings curated for this source.
PMID:40668560
MALDI-MSI reveals shared lipid signatures in sarcoid-like granulomas of mice and in a human case.
No top-level findings curated for this source.
PMID:40702280
Comparing the efficacy and safety of cyclophosphamide, infliximab and methotrexate in neurosarcoidosis: a multicenter retrospective study.
No top-level findings curated for this source.
PMID:40769406
Cognitive impairment in systemic autoimmune and inflammatory diseases: A narrative review focused on ANCA-associated vasculitis, sarcoidosis, Sjögren's syndrome, systemic sclerosis, and Behçet's disease.
No top-level findings curated for this source.
PMID:41015397
Comparison of the effects of one-legged and two-legged exercise training on exercise capacity and fatigue in patients with sarcoidosis.
No top-level findings curated for this source.
PMID:41054684
A Fulminant Case of Refractory Sarcoidosis Triggered by Infliximab-Neutralizing Antibodies.
No top-level findings curated for this source.
PMID:41213628
Biomarkers in Sarcoidosis: From Traditional Markers to Precision Medicine.
No top-level findings curated for this source.
PMID:41218636
Small Fiber Neuropathy in Sarcoidosis.
No top-level findings curated for this source.
PMID:41316274
The interplay between M2-like macrophages and Th17.1 cells promotes the progression of early-stage sarcoidosis.
No top-level findings curated for this source.
PMID:41371265
Neurosarcoidosis in Critical Care, Internal, and Pulmonary Medicine: A Practical Approach.
No top-level findings curated for this source.
PMID:41380938
TEAM Sarcoidosis: Creating a Multidisciplinary Care Team for Complex Clinical Management.
No top-level findings curated for this source.
PMID:41429672
Neuro-Ophthalmic Manifestations of Neurosarcoidosis.
No top-level findings curated for this source.
PMID:41459541
Clinical updates of JAK inhibitors in cutaneous granulomatous diseases.
No top-level findings curated for this source.
PMID:41476976
βc receptor antagonism mitigates sarcoidosis granuloma formation by targeting inflammatory signals and aberrant lipid metabolism.
No top-level findings curated for this source.
PMID:41651390
Sarcoidosis: Disease mechanisms, diagnostic pathway and treatment.
No top-level findings curated for this source.
PMID:42084847
Extracellular vimentin promotes neutrophil-dominant granulomatous inflammation in progressive pulmonary sarcoidosis.
No top-level findings curated for this source.
PMID:15925652
Sarcoidosis.
No top-level findings curated for this source.
PMID:30167654
Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group.
No top-level findings curated for this source.
PMID:32404428
Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system.
No top-level findings curated for this source.
PMID:34215779
Clinical characterization and outcomes of 85 patients with neurosarcoidosis.
No top-level findings curated for this source.
PMID:37034091
Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction.
No top-level findings curated for this source.
PMID:39193252
Diagnostic value of soluble Interleukin-2 receptor in patients suffering neurosarcoidosis: A systematic review.
No top-level findings curated for this source.
PMID:39398844
Neurosarcoidosis: Current Perspectives on Diagnosis, Management, and Future Directions.
No top-level findings curated for this source.

Deep Research

2
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 47 citations 2026-05-16T05:12:36.547320

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Neurosarcoidosis
  • MONDO ID: (if available)
  • Category: Immune

Research Objectives

Please provide a comprehensive research report on Neurosarcoidosis covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Neurosarcoidosis — Disease Characteristics Research Report (Immune)

Executive summary

Neurosarcoidosis (NS) is a granulomatous inflammatory disorder of the central and/or peripheral nervous system that occurs in the setting of systemic sarcoidosis or as isolated nervous-system disease. Modern practice is anchored by the 2018 Neurosarcoidosis Consortium Consensus Group diagnostic-certainty framework (“possible/probable/definite”) and a systematic exclusion of key mimics (notably infection and malignancy), because no single clinical sign, imaging feature, or biomarker is pathognomonic. Recent (2023–2024) cohorts and systematic reviews reinforce: (i) high diagnostic yield from contrast MRI plus CSF studies; (ii) increasing use of FDG-PET/CT to locate extra-neural biopsy targets; (iii) evolving biomarker evidence for soluble IL-2 receptor (sIL-2R) and CSF indices; and (iv) strong—though largely non-randomized—evidence supporting TNF-α inhibitors (especially infliximab) for refractory/aggressive disease, with clinically meaningful relapse risk when biologics are discontinued. (stern2018definitionandconsensus pages 5-6, vlad2023differentiatingneurosarcoidosisfrom pages 4-5, chanpura2024diagnosticvalueof pages 6-7, chaiyanarm2024infliximabinneurosarcoidosis pages 6-8)

Domain Measure Value(s) Study/citation details
Epidemiology Frequency among sarcoidosis patients Clinically overt neurosarcoidosis in up to 10% of sarcoidosis patients Ungprasert et al. 2022, Expert Review of Neurotherapeutics; DOI: 10.1080/14737175.2022.2108705; https://doi.org/10.1080/14737175.2022.2108705 (ungprasert2022neurosarcoidosisanupdate pages 1-3)
Epidemiology Frequency among sarcoidosis patients About 5% of sarcoidosis patients develop neurosarcoidosis Basheer et al. 2023, Life; DOI: 10.3390/life14010069; https://doi.org/10.3390/life14010069 (basheer2023neurosarcoidosisthepresentation pages 7-8)
Epidemiology Frequency among sarcoidosis patients 5.5% (85/1532) fulfilled Stern criteria for neurosarcoidosis Ramos-Casals et al. 2021, Scientific Reports; DOI: 10.1038/s41598-021-92967-6; https://doi.org/10.1038/s41598-021-92967-6 (sambon2022epidemiologyclinicalpresentation pages 1-2)
Epidemiology Systemic sarcoidosis coexistence 86% in local cohort; 83% in literature review had systemic sarcoidosis Sambon et al. 2022, Frontiers in Neurology; DOI: 10.3389/fneur.2022.970168; https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 1-2)
Clinical phenotypes Common presenting features Cranial neuropathies 38%, motor deficit 32%, headache 16%, pituitary dysfunction 12% Berntsson et al. 2023, Scientific Reports; DOI: 10.1038/s41598-023-33631-z; https://doi.org/10.1038/s41598-023-33631-z (sambon2022epidemiologyclinicalpresentation pages 1-2)
Clinical phenotypes CNS distribution Brain 38%, cranial nerves 36%, meninges 3%, spinal cord 10%, peripheral nerves 14% Ramos-Casals et al. 2021, Scientific Reports; DOI: 10.1038/s41598-021-92967-6; https://doi.org/10.1038/s41598-021-92967-6 (sambon2022epidemiologyclinicalpresentation pages 1-2)
Clinical phenotypes Initial manifestations in national cohort Cranial nerve palsies 36%, medullary symptoms 23%, seizures 21% Dos Santos et al. 2024, Brain and Behavior; DOI: 10.1002/brb3.3443; https://doi.org/10.1002/brb3.3443 (santos2024neurosarcoidosisclinicalbiological pages 1-2)
Clinical phenotypes Cognitive symptoms Cognitive failure 16.9% overall; 24.3% in group 1, 13.8% in group 2 Dos Santos et al. 2024, Brain and Behavior; DOI: 10.1002/brb3.3443; https://doi.org/10.1002/brb3.3443 (santos2024neurosarcoidosisclinicalbiological pages 8-9)
CSF findings Overall CSF abnormality 77% abnormal CSF studies Berntsson et al. 2023, Scientific Reports; DOI: 10.1038/s41598-023-33631-z; https://doi.org/10.1038/s41598-023-33631-z (sambon2022epidemiologyclinicalpresentation pages 1-2)
CSF findings Specific abnormalities Lymphocytosis 57%, elevated protein 44%, oligoclonal bands 40%, elevated CSF ACE 28%, raised CSF CD4+/CD8+ ratio 13% Berntsson et al. 2023, Scientific Reports; DOI: 10.1038/s41598-023-33631-z; https://doi.org/10.1038/s41598-023-33631-z (sambon2022epidemiologyclinicalpresentation pages 1-2)
CSF findings Local cohort lumbar puncture 15/22 tested; abnormal in all patients Sambon et al. 2022, Frontiers in Neurology; DOI: 10.3389/fneur.2022.970168; https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 1-2)
CSF findings Cohort workup Lumbar puncture in 54; 42/54 abnormal (78%) Berntsson et al. 2023, Scientific Reports; DOI: 10.1038/s41598-023-33631-z; https://doi.org/10.1038/s41598-023-33631-z (berntsson2023acomprehensivediagnostic pages 6-7)
CSF findings Meta-analytic abnormality ranges Pleocytosis in 32–63%; increased protein in 46–76%; meta-analysis: increased WCC 58%, elevated protein 63% Vlad et al. 2023, Frontiers in Neurology; DOI: 10.3389/fneur.2023.1135392; https://doi.org/10.3389/fneur.2023.1135392 (vlad2023differentiatingneurosarcoidosisfrom pages 9-10)
Imaging findings Brain MRI abnormalities Brain MRI abnormal in 16/21; parenchymal lesions 63%, hypothalamic-pituitary lesions 38%, meningeal enhancement 31% Sambon et al. 2022, Frontiers in Neurology; DOI: 10.3389/fneur.2022.970168; https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 1-2)
Imaging findings Pituitary involvement Isolated pituitary gland lesions in 17% Berntsson et al. 2023, Scientific Reports; DOI: 10.1038/s41598-023-33631-z; https://doi.org/10.1038/s41598-023-33631-z (sambon2022epidemiologyclinicalpresentation pages 1-2)
Imaging findings MRI sensitivity MRI with gadolinium sensitivity 82–97% Sambon et al. 2022, Frontiers in Neurology; DOI: 10.3389/fneur.2022.970168; https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 14-16)
Imaging findings MRI positivity in cohort Brain MRI abnormal in 61/61; spinal MRI abnormal in 15/47 (32%) Berntsson et al. 2023, Scientific Reports; DOI: 10.1038/s41598-023-33631-z; https://doi.org/10.1038/s41598-023-33631-z (berntsson2023acomprehensivediagnostic pages 6-7)
Imaging findings MRI positivity in NS vs MS cohort MRI abnormalities in 88.9%; leptomeningeal enhancement 59.3%; supratentorial 70.4%; infratentorial 44.4%; spinal 22.2%; normal MRI 11.1% Vlad et al. 2023, Frontiers in Neurology; DOI: 10.3389/fneur.2023.1135392; https://doi.org/10.3389/fneur.2023.1135392 (vlad2023differentiatingneurosarcoidosisfrom pages 4-5, vlad2023differentiatingneurosarcoidosisfrom pages 2-3)
Imaging findings FDG-PET/CT yield FDG-PET/CT abnormal in 11/22 (50%) in one cohort Berntsson et al. 2023, Scientific Reports; DOI: 10.1038/s41598-023-33631-z; https://doi.org/10.1038/s41598-023-33631-z (berntsson2023acomprehensivediagnostic pages 6-7)
Imaging findings FDG-PET yield FDG-PET/CT detected abnormalities in 85% in cohort Sambon et al. 2022, Frontiers in Neurology; DOI: 10.3389/fneur.2022.970168; https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 14-16)
Imaging findings FDG-PET systemic lesion detection Sarcoidosis-typical systemic lesions/abnormalities in 15/16 (93.8%) Vlad et al. 2023, Frontiers in Neurology; DOI: 10.3389/fneur.2023.1135392; https://doi.org/10.3389/fneur.2023.1135392 (vlad2023differentiatingneurosarcoidosisfrom pages 2-3)
Biomarkers Serum routine markers in local cohort CRP elevated 33%, calcemia 18%, lysozyme 79%, serum ACE 16% Sambon et al. 2022, Frontiers in Neurology; DOI: 10.3389/fneur.2022.970168; https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 1-2)
Biomarkers Serum/CSF sIL-2R and ACE performance Serum sIL-2R sensitivity 88%, specificity 85%; ACE sensitivity 62%, specificity 76% Sinha et al. 2024, Cureus; DOI: 10.7759/cureus.69208; https://doi.org/10.7759/cureus.69208 (sinha2024neurosarcoidosiscurrentperspectives pages 4-6)
Biomarkers CSF ACE performance CSF ACE cut-off 2: sensitivity 66.7%, specificity 67.3% Sinha et al. 2024, Cureus; DOI: 10.7759/cureus.69208; https://doi.org/10.7759/cureus.69208 (sinha2024neurosarcoidosiscurrentperspectives pages 4-6)
Biomarkers CSF ACE in cohort 19/35 abnormal; specificity ~94–95%, sensitivity 24–55% Berntsson et al. 2023, Scientific Reports; DOI: 10.1038/s41598-023-33631-z; https://doi.org/10.1038/s41598-023-33631-z (berntsson2023acomprehensivediagnostic pages 6-7)
Biomarkers sIL-2R systematic review size 6 studies; 98 neurosarcoidosis, 525 non-sarcoidosis, 118 healthy controls Chanpura et al. 2024, Journal of Central Nervous System Disease; DOI: 10.1177/11795735241274186; https://doi.org/10.1177/11795735241274186 (chanpura2024diagnosticvalueof pages 1-2)
Biomarkers CSF sIL-2R cutoff performance Cutoff 150 pg/mL: sensitivity 61%, specificity 93%, accuracy 0.83 Chanpura et al. 2024, Journal of Central Nervous System Disease; DOI: 10.1177/11795735241274186; https://doi.org/10.1177/11795735241274186 (chanpura2024diagnosticvalueof pages 6-7)
Biomarkers sIL-2R index AUC vs multiple sclerosis 0.724; active disease median 32.45 vs remission 7.18 (P=0.0016) Chanpura et al. 2024, Journal of Central Nervous System Disease; DOI: 10.1177/11795735241274186; https://doi.org/10.1177/11795735241274186 (chanpura2024diagnosticvalueof pages 6-7)
Biomarkers sIL-2R frequencies in NS cohort Serum elevated 10/25 (40.0%); CSF elevated 9/21 (42.9%); serum and/or CSF elevated 16/25 (64.0%) Vlad et al. 2023, Frontiers in Neurology; DOI: 10.3389/fneur.2023.1135392; https://doi.org/10.3389/fneur.2023.1135392 (vlad2023differentiatingneurosarcoidosisfrom pages 2-3)
Biomarkers Neopterin in NS cohort Serum and/or CSF elevated 19/22 (86.4%) Vlad et al. 2023, Frontiers in Neurology; DOI: 10.3389/fneur.2023.1135392; https://doi.org/10.3389/fneur.2023.1135392 (vlad2023differentiatingneurosarcoidosisfrom pages 2-3)
Biomarkers Diagnostic likelihood ratios PLR: WCC >30/µL = 7.2; QAlb >10×10⁻³ = 66.4; absence of CSF-specific OCB = 11.5; elevated CSF lactate = 23.0; elevated sIL-2R >8.0 Vlad et al. 2023, Frontiers in Neurology; DOI: 10.3389/fneur.2023.1135392; https://doi.org/10.3389/fneur.2023.1135392 (vlad2023differentiatingneurosarcoidosisfrom pages 1-2)
Biomarkers Best combined CSF rule Sensitivity and specificity each >92%; PLR 12.8; NLR 0.08 Vlad et al. 2023, Frontiers in Neurology; DOI: 10.3389/fneur.2023.1135392; https://doi.org/10.3389/fneur.2023.1135392 (vlad2023differentiatingneurosarcoidosisfrom pages 1-2)
Treatment outcomes Methotrexate usage/outcome Most frequently used second-line therapy (>45% of cases); favorable outcome in average 50% Sambon et al. 2022, Frontiers in Neurology; DOI: 10.3389/fneur.2022.970168; https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 1-2)
Treatment outcomes TNF-α antagonist use 9% in local cohort; 27% in literature review Sambon et al. 2022, Frontiers in Neurology; DOI: 10.3389/fneur.2022.970168; https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 1-2)
Treatment outcomes Overall pooled favorable outcome 282/354 (80%) favorable; 39/354 (11%) relapse/progression; 1/354 (0.3%) died Sambon et al. 2022, Frontiers in Neurology; DOI: 10.3389/fneur.2022.970168; https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 14-16)
Treatment outcomes Infliximab meta-analysis Pooled clinical improvement 74% (95% CI 64–84%) Chaiyanarm et al. 2024, Annals of Clinical and Translational Neurology; DOI: 10.1002/acn3.51968; https://doi.org/10.1002/acn3.51968 (chaiyanarm2024infliximabinneurosarcoidosis pages 6-8, chaiyanarm2024infliximabinneurosarcoidosis pages 1-2)
Treatment outcomes Infliximab adverse events 52/177 patients (29.4%) had adverse events; infections were 72.2% of events Chaiyanarm et al. 2024, Annals of Clinical and Translational Neurology; DOI: 10.1002/acn3.51968; https://doi.org/10.1002/acn3.51968 (chaiyanarm2024infliximabinneurosarcoidosis pages 1-2, chaiyanarm2024infliximabinneurosarcoidosis pages 2-3)
Treatment outcomes Cohort infliximab outcome Complete remission 6 (21%), improvement 14 (50%), stable disease 7 (25%), deterioration/death 1 (4%) Basheer et al. 2023, Life; DOI: 10.3390/life14010069; https://doi.org/10.3390/life14010069 (basheer2023neurosarcoidosisthepresentation pages 7-8)
Relapse/discontinuation TNF-α antagonist discontinuation 70/223 (31%) discontinued Sambon et al. 2022, Frontiers in Neurology; DOI: 10.3389/fneur.2022.970168; https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 14-16)
Relapse/discontinuation Relapse after stopping TNF-α antagonists 14/28 (50%) relapsed after discontinuation Sambon et al. 2022, Frontiers in Neurology; DOI: 10.3389/fneur.2022.970168; https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 13-14, sambon2022epidemiologyclinicalpresentation pages 14-16)
Relapse/discontinuation Infliximab pooled relapse 38% (95% CI 22–55%) Chaiyanarm et al. 2024, Annals of Clinical and Translational Neurology; DOI: 10.1002/acn3.51968; https://doi.org/10.1002/acn3.51968 (chaiyanarm2024infliximabinneurosarcoidosis pages 6-8, chaiyanarm2024infliximabinneurosarcoidosis pages 1-2)
Relapse/discontinuation Relapse after infliximab reduction/discontinuation 18/30 (60%) relapsed after stopping or reducing infliximab Chaiyanarm et al. 2024, Annals of Clinical and Translational Neurology; DOI: 10.1002/acn3.51968; https://doi.org/10.1002/acn3.51968 (chaiyanarm2024infliximabinneurosarcoidosis pages 2-3)
Relapse/discontinuation Corticosteroid taper/stop 77/110 (70%) tapered or stopped corticosteroids Sambon et al. 2022, Frontiers in Neurology; DOI: 10.3389/fneur.2022.970168; https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 14-16)
Clinical trials Observational disease-course study NCT04911348; retrospective multicenter cohort; enrollment ~80; follow-up ~6 years ClinicalTrials.gov 2021; https://clinicaltrials.gov/study/NCT04911348 (NCT04911348 chunk 1)
Clinical trials ACTHAR trial NCT02920710; Phase 4; withdrawn; actual enrollment 0; primary endpoint at 12 weeks ClinicalTrials.gov 2019; https://clinicaltrials.gov/study/NCT02920710 (NCT02920710 chunk 1)
Clinical trials Advanced sarcoidosis registry NCT03769987; observational registry; enrollment 800; primary endpoint death over 2 years ClinicalTrials.gov 2017; https://clinicaltrials.gov/study/NCT03769987 (NCT03769987 chunk 1)
Clinical trials Biomarker diagnostic study NCT05056740; observational retrospective biomarker study; enrollment 300; estimated completion 2025-11-01 ClinicalTrials.gov 2020; https://clinicaltrials.gov/study/NCT05056740 (NCT05056740 chunk 1)

Table: This table compiles explicit quantitative findings on neurosarcoidosis across epidemiology, phenotypes, diagnostics, biomarkers, treatment outcomes, relapse, and ongoing clinical research. It is useful as a quick reference for evidence-supported values and the studies from which they were drawn.

1. Disease information

1.1 Overview / definition

The most widely cited contemporary definition and diagnostic framework comes from the Neurosarcoidosis Consortium Consensus Group (NCCG) (Stern et al., JAMA Neurology, published Dec 2018; https://doi.org/10.1001/jamaneurol.2018.2295). The abstract states the criteria “provide definitions for possible, probable, and definite central and peripheral nervous system sarcoidosis” and “emphasize the need to evaluate patients…for alternate causal factors, including infection and malignant neoplasm,” with biopsy recommended “whenever feasible” (stern2018definitionandconsensus pages 1-2).

Consensus diagnostic-certainty categories (2018 NCCG): - Possible NS: clinical presentation plus MRI/CSF and/or EMG/NCS findings typical of granulomatous inflammation of the nervous system after rigorous exclusion of other causes, but no pathologic confirmation of granulomatous disease. (stern2018definitionandconsensus pages 5-6) - Probable NS: same clinical/paraclinical pattern and exclusion of other causes, plus pathologic confirmation of systemic granulomatous disease consistent with sarcoidosis (extraneural biopsy). (stern2018definitionandconsensus pages 5-6) - Definite NS: same clinical/paraclinical pattern and exclusion of other causes, plus nervous system pathology consistent with NS; “definite” is subclassified as type a (extraneural sarcoidosis evident) or type b (isolated CNS disease without extraneural sarcoidosis). (stern2018definitionandconsensus pages 5-6)

1.2 Identifiers and ontology cross-references

  • MONDO / Orphanet / OMIM / MeSH / ICD-10/ICD-11: Not retrieved directly in the current tool run (ontology database lookups were not available among tools used). This report therefore emphasizes primary clinical consensus definitions and peer‑reviewed literature rather than curated identifier pages.

1.3 Common synonyms / alternative names

Common usage in the literature includes: - “Neurosarcoidosis” - “Central nervous system sarcoidosis” / “CNS sarcoidosis” - “Peripheral nervous system sarcoidosis” / “PNS sarcoidosis” - “Isolated neurosarcoidosis” / “isolated CNS sarcoidosis” (corresponding to “definite type b” in NCCG) (stern2018definitionandconsensus pages 5-6)

1.4 Evidence type note (individual vs aggregated)

Evidence in this report is drawn from (i) expert consensus criteria (NCCG 2018), (ii) retrospective cohorts (e.g., national multicenter cohort, tertiary-center cohorts), and (iii) systematic reviews/meta-analyses (especially for infliximab and for sIL-2R biomarker performance). (stern2018definitionandconsensus pages 5-6, berntsson2023acomprehensivediagnostic pages 6-7, chanpura2024diagnosticvalueof pages 6-7, chaiyanarm2024infliximabinneurosarcoidosis pages 6-8)

2. Etiology

2.1 Disease causal factors

NS is generally treated as an immune-mediated granulomatous inflammatory manifestation of sarcoidosis affecting nervous tissue, rather than a monogenic disorder; the NCCG explicitly notes diagnostic uncertainty and the lack of a pathognomonic histology/test, reflecting mechanistic heterogeneity. (stern2018definitionandconsensus pages 1-2)

2.2 Risk factors

Established, disease-specific genetic risk factors (causal variants) were not identified in the retrieved NS-focused evidence, and the literature used here largely treats NS risk as part of systemic sarcoidosis risk and immune dysregulation rather than Mendelian inheritance.

2.3 Protective factors / gene–environment interaction

Not established from the retrieved NS-specific sources.

3. Phenotypes (clinical manifestations)

3.1 Typical age of onset

In one structured diagnostic cohort (Sweden, 1990–2021), the median age at symptom onset was 49 years with similar sex distribution. (sambon2022epidemiologyclinicalpresentation pages 1-2)

3.2 Common presenting features (with frequencies where available)

Recent cohorts highlight broad phenotype heterogeneity: - Cranial neuropathies (38%), motor deficit (32%), headache (16%), pituitary dysfunction (12%) in a tertiary-center cohort. (sambon2022epidemiologyclinicalpresentation pages 1-2) - In a national multicenter French cohort (2010–2019 hospitalizations), NS presented initially in 78%, with cranial nerve palsies 36%, medullary symptoms 23%, and seizures 21%. (santos2024neurosarcoidosisclinicalbiological pages 1-2) - Cognitive manifestations: cognitive failure 16.9% in the national cohort. (santos2024neurosarcoidosisclinicalbiological pages 8-9)

3.3 Suggested HPO terms (examples)

(Provide for knowledge base population; frequencies depend on cohort and phenotype definition) - Cranial neuropathy / facial palsy: HP:0001284 (Cranial nerve disease), HP:0007209 (Facial palsy) - Headache: HP:0002315 (Headache) - Seizure: HP:0001250 (Seizures) - Motor deficit / weakness: HP:0001324 (Muscle weakness), HP:0002355 (Motor delay/deficit) - Myelitis / spinal cord involvement: HP:0002303 (Myelitis) - Pituitary dysfunction: HP:0000874 (Pituitary insufficiency) - Cognitive impairment: HP:0100543 (Cognitive impairment)

3.4 Quality-of-life impact

Direct QoL instrument statistics (e.g., SF‑36, EQ‑5D) were not captured in retrieved excerpts. However, the NCCG and contemporary reviews emphasize disability risk and diagnostic/treatment urgency for potentially reversible inflammatory disease, implying significant functional impact when CNS/PNS structures are involved. (stern2018definitionandconsensus pages 1-2, ungprasert2022neurosarcoidosisanupdate pages 1-3)

4. Genetic / molecular information

4.1 Causal genes / variants

No validated single-gene causal etiology was identified in the retrieved NS-focused literature. NS is best treated here as an immune-mediated phenotype within the sarcoidosis spectrum.

4.2 Molecular / biomarker signals (human clinical evidence)

  • TNF‑α relevance: TNF‑α inhibitors are used for refractory NS, reflecting TNF‑α’s importance in granuloma biology (supported indirectly by treatment effectiveness data; see Treatment). (chaiyanarm2024infliximabinneurosarcoidosis pages 6-8)
  • Cytokine and inflammatory biomarker elevation: A 2024 review summarizes that multiple CSF cytokines (e.g., IL‑6 and others) have been reported elevated in NS and that sIL‑2R may outperform ACE in some datasets; however, heterogeneity and limited prospective validation remain key limitations. (sinha2024neurosarcoidosiscurrentperspectives pages 4-6)

4.3 Suggested ontology terms

  • GO biological process (examples): granuloma-related inflammatory response; T‑cell activation; cytokine-mediated signaling.
  • CL (cell types; examples): activated CD4-positive T cell (CL:0000624), macrophage (CL:0000235).
  • CHEBI (biomarker chemicals; examples): angiotensin-converting enzyme (protein biomarker; not CHEBI), interleukin-2 receptor (protein biomarker).

5. Environmental information

Direct environmental triggers specific to NS were not established from the retrieved evidence; differential diagnosis strongly prioritizes ruling out infectious granulomatous diseases (e.g., tuberculosis, fungal infection), underscoring the clinical importance of environmental/infectious exposures as mimics. (sambon2022epidemiologyclinicalpresentation pages 14-16, stern2018definitionandconsensus pages 1-2)

6. Mechanism / pathophysiology

6.1 Current understanding (causal chain)

A practical, evidence-aligned mechanistic chain (human clinical inference) is: 1) systemic immune dysregulation producing granulomatous inflammation (sarcoidosis spectrum) 2) granulomatous inflammation within CNS/PNS compartments 3) lesion-location–specific neurologic dysfunction (e.g., cranial neuropathies, seizures, meningitis, pituitary dysfunction) 4) potential progression to fixed deficits if inflammation persists or leads to tissue damage.

This chain is consistent with the NCCG emphasis on heterogeneous presentations and lack of a single conclusive diagnostic test. (stern2018definitionandconsensus pages 1-2)

6.2 Immune system involvement

CSF and imaging evidence commonly demonstrate intrathecal inflammation: - In a tertiary-center cohort, CSF studies were abnormal in 77% and included lymphocytosis and elevated protein in substantial fractions. (sambon2022epidemiologyclinicalpresentation pages 1-2) - A meta-analytic range summarized in a 2023 differential diagnostic cohort paper: CSF pleocytosis 32–63% and elevated protein 46–76%; meta-analysis reported increased WCC 58% and elevated protein 63%. (vlad2023differentiatingneurosarcoidosisfrom pages 9-10)

6.3 Suggested GO and CL terms

  • GO (examples): leukocyte activation, T cell activation, cytokine production, granuloma formation.
  • CL (examples): T lymphocyte subsets (CD4+), macrophages.

7. Anatomical structures affected

7.1 Organ/system level

NS affects: - Central nervous system: brain parenchyma, leptomeninges, pituitary/hypothalamus; seizure presentations are reported. (santos2024neurosarcoidosisclinicalbiological pages 1-2, sambon2022epidemiologyclinicalpresentation pages 1-2) - Peripheral nervous system: cranial nerves and peripheral nerves; cranial nerve palsies are common. (santos2024neurosarcoidosisclinicalbiological pages 1-2, sambon2022epidemiologyclinicalpresentation pages 1-2)

7.2 Suggested UBERON terms (examples)

  • UBERON:0000955 (brain)
  • UBERON:0001017 (central nervous system)
  • UBERON:0001032 (peripheral nervous system)
  • UBERON:0000007 (pituitary gland)
  • UBERON:0002078 (meninges/leptomeninges)

8. Temporal development

8.1 Onset and course patterns

NS can present as an initial manifestation of sarcoidosis or later in systemic disease; a French multicenter cohort reported NS presented initially in 78%. (santos2024neurosarcoidosisclinicalbiological pages 1-2)

8.2 Relapse patterns

Relapse risk is clinically important, especially around treatment discontinuation: - In pooled anti‑TNF cohorts, relapse/progression occurred in 11% (39/354) overall, and among those with follow-up after stopping TNF‑α antagonists, 50% (14/28) relapsed. (sambon2022epidemiologyclinicalpresentation pages 13-14, sambon2022epidemiologyclinicalpresentation pages 14-16) - In an infliximab meta-analysis (Dec 2024), pooled relapse rate was 38% (95% CI 22–55%), and a substantial fraction of relapses were associated with infliximab discontinuation. (chaiyanarm2024infliximabinneurosarcoidosis pages 6-8)

9. Inheritance and population

9.1 Epidemiology (NS frequency)

Across reviews and cohorts, NS is typically estimated at ~5–10% of sarcoidosis patients: - “Clinically overt… can be seen in up to 10% of patients with sarcoidosis.” (Ungprasert et al., Aug 2022; https://doi.org/10.1080/14737175.2022.2108705) (ungprasert2022neurosarcoidosisanupdate pages 1-3) - A 2023 review states NS occurs in about 5% of sarcoidosis patients. (Basheer et al., Dec 2023; https://doi.org/10.3390/life14010069) (basheer2023neurosarcoidosisthepresentation pages 7-8)

NS population-level incidence/prevalence (per 100,000) was not identified in the retrieved evidence excerpts; available evidence more often reports proportion among sarcoidosis or cohort frequencies.

9.2 Systemic disease association

In a cohort plus literature review synthesis, NS occurred most frequently in the setting of systemic sarcoidosis: 86% (local cohort) and 83% (literature review). (sambon2022epidemiologyclinicalpresentation pages 1-2)

9.3 Inheritance pattern

No Mendelian inheritance pattern is supported by the retrieved NS-focused sources.

10. Diagnostics

10.1 Clinical criteria and diagnostic certainty (2018 NCCG)

The 2018 NCCG framework is now a central real-world diagnostic standard, explicitly requiring (i) compatible clinical syndrome with supportive MRI/CSF/EMG evidence and (ii) rigorous exclusion of mimics, with (iii) escalating certainty based on biopsy evidence (extraneural for “probable,” neural for “definite,” none for “possible”). (stern2018definitionandconsensus pages 5-6, stern2018definitionandconsensus pages 1-2)

Direct abstract quote (NCCG 2018, JAMA Neurology): the criteria “emphasize the need to evaluate patients with findings suggestive of neurosarcoidosis for alternate causal factors, including infection and malignant neoplasm.” (stern2018definitionandconsensus pages 1-2)

10.2 Imaging

  • MRI with gadolinium is widely treated as the imaging cornerstone; a cohort/literature synthesis reports MRI sensitivity 82–97%. (sambon2022epidemiologyclinicalpresentation pages 14-16)
  • MRI phenotypes that can support differentiation from MS include leptomeningeal enhancement (reported in 59.3% in a 27‑patient NS cohort), which is relatively rare in MS. (vlad2023differentiatingneurosarcoidosisfrom pages 2-3)
  • FDG-PET/CT: used primarily to detect systemic disease and identify biopsy targets; yields vary by setting—e.g., in one cohort FDG-PET/CT was abnormal in 11/22 (50%), while in an NS vs MS diagnostic cohort it identified systemic sarcoidosis‑typical lesions in 15/16 (93.8%). (berntsson2023acomprehensivediagnostic pages 6-7, vlad2023differentiatingneurosarcoidosisfrom pages 2-3)

10.3 CSF testing and biomarkers

CSF abnormalities are common but not specific: - In one diagnostic cohort, lumbar puncture was abnormal in 42/54 (78%). (berntsson2023acomprehensivediagnostic pages 6-7) - In another center’s cohort, CSF was abnormal in 77%, with lymphocytosis, elevated protein, oligoclonal bands, and elevated CSF ACE occurring in subsets. (sambon2022epidemiologyclinicalpresentation pages 1-2)

Soluble IL‑2 receptor (sIL‑2R): - A 2024 systematic review (Aug 2024; https://doi.org/10.1177/11795735241274186) found that CSF sIL‑2R differs between NS and mimics and that an sIL‑2R index is higher in active disease (median 32.45) than remission (median 7.18; P=0.0016). (chanpura2024diagnosticvalueof pages 6-7) - One included study in that review reported CSF sIL‑2R cutoff 150 pg/mL with sensitivity 61% and specificity 93%. (chanpura2024diagnosticvalueof pages 6-7)

Differentiating NS from MS (Frontiers in Neurology 2023; https://doi.org/10.3389/fneur.2023.1135392): - Very strong rule-in value was reported for blood–CSF barrier dysfunction: QAlb >10×10−3 PLR 66.4; absence of CSF-specific OCB PLR 11.5; elevated CSF lactate PLR 23.0; elevated sIL‑2R PLR >8. (vlad2023differentiatingneurosarcoidosisfrom pages 1-2) - A combined rule (one of WCC>30/µl or QAlb>10×10−3 or absent CSF OCB plus absent MRZ reaction) achieved sensitivity and specificity each >92% (PLR 12.8; NLR 0.08). (vlad2023differentiatingneurosarcoidosisfrom pages 1-2)

10.4 Differential diagnosis (key mimics to exclude)

The NCCG and cohorts emphasize systematic exclusion of: - Infection: tuberculosis/mycobacteria, fungal disease, etc. - Malignancy: lymphoma and other neoplasms - Other inflammatory/autoimmune conditions, depending on phenotype (e.g., myelitis workup including AQP4/MOG). (sambon2022epidemiologyclinicalpresentation pages 14-16, stern2018definitionandconsensus pages 1-2)

10.5 Visual evidence (diagnostic workup tables)

Berntsson et al. (Scientific Reports, Apr 2023; https://doi.org/10.1038/s41598-023-33631-z) provides tabulated diagnostic work-up and diagnostic classification summaries useful for real-world implementation reference. (berntsson2023acomprehensivediagnostic media 360bc208, berntsson2023acomprehensivediagnostic media bbaa5c3a, berntsson2023acomprehensivediagnostic media 2e1b352e)

11. Outcome / prognosis

Outcome data are heterogeneous and depend on phenotype and treatment intensity. In a large pooled analysis focused on TNF‑α inhibitor–treated patients, outcomes were favorable in 80% (282/354) with relapse/progression 11% and NS-related mortality 0.3% (noting these are treated cohorts rather than unselected natural history). (sambon2022epidemiologyclinicalpresentation pages 14-16)

A 2024 infliximab meta-analysis reported a pooled clinical improvement rate of 74% and pooled relapse rate of 38%. (chaiyanarm2024infliximabinneurosarcoidosis pages 6-8)

12. Treatment

12.1 Core concepts / treatment strategy (current understanding)

Treatment recommendations remain largely expert-opinion driven due to limited randomized trial data. A practical escalation approach is reflected across reviews and cohorts: 1) Glucocorticoids as first-line therapy 2) Steroid-sparing immunosuppressants (e.g., methotrexate, azathioprine, mycophenolate) for steroid dependence or moderate–severe disease 3) Biologics, particularly TNF‑α inhibitors (infliximab; adalimumab) for aggressive or refractory NS. (ungprasert2022neurosarcoidosisanupdate pages 9-10, basheer2023neurosarcoidosisthepresentation pages 6-7)

12.2 Recent developments (2023–2024)

Infliximab evidence strengthened by meta-analysis (Dec 2024): - Pooled improvement 74% (95% CI 64–84%) and relapse 38% (95% CI 22–55%), with infections comprising most adverse events. (Chaiyanarm et al., Ann Clin Transl Neurol, Dec 2024; https://doi.org/10.1002/acn3.51968) (chaiyanarm2024infliximabinneurosarcoidosis pages 6-8, chaiyanarm2024infliximabinneurosarcoidosis pages 1-2)

Comparative effectiveness synthesis (Frontiers Neurology 2022 cohort + literature review): - Anti‑TNF therapy was associated with significantly higher favorable outcomes than methotrexate, mycophenolate mofetil, or azathioprine (reported reciprocal ORs vs methotrexate 4.68; vs mycophenolate 5.89; vs azathioprine 5.26). (sambon2022epidemiologyclinicalpresentation pages 13-14)

12.3 Real-world implementation details and monitoring

  • Steroid tapering/cessation was possible in many treated cohorts (e.g., pooled data show corticosteroids tapered or stopped in 70% (77/110)). (sambon2022epidemiologyclinicalpresentation pages 14-16)
  • Relapse after TNF‑α discontinuation is frequent (50% in those with follow-up after stopping TNF‑α antagonists). (sambon2022epidemiologyclinicalpresentation pages 13-14)
  • Before TNF‑α inhibitors, practical screening for latent infections (e.g., TB) and viral infections is emphasized in clinical reviews. (basheer2023neurosarcoidosisthepresentation pages 7-8)

12.4 Suggested MAXO terms (examples)

  • MAXO:0000746 (Glucocorticoid therapy)
  • MAXO:0000602 (Immunosuppressive therapy)
  • MAXO:0001020 (Tumor necrosis factor inhibitor therapy)

13. Prevention

No primary prevention strategy specific to NS is established in the retrieved sources. Secondary/tertiary prevention in practice focuses on early recognition, exclusion of mimics, and early treatment of potentially reversible inflammatory disease, as emphasized by the NCCG. (stern2018definitionandconsensus pages 1-2)

14. Other species / natural disease

Not established from the retrieved evidence.

15. Model organisms

Not established from the retrieved evidence.

Clinical trials and research landscape (real-world implementations)

Recent and ongoing research is predominantly observational/registry-based: - NCT04911348 (Neurosarcoidosis: Initial Presentation and Disease Course; ClinicalTrials.gov; multicenter retrospective observational cohort; start 2021; https://clinicaltrials.gov/study/NCT04911348): aims to categorize disease course patterns over long follow-up using chart review and MRI/clinical data. (NCT04911348 chunk 1) - NCT02920710 (ACTHAR Therapy for CNS Sarcoidosis; start 2019; https://clinicaltrials.gov/study/NCT02920710): Phase 4 open-label repository corticotropin trial; withdrawn due to recruitment difficulty; enrollment 0. (NCT02920710 chunk 1) - NCT03769987 (Registry for Advanced Sarcoidosis; start 2017; https://clinicaltrials.gov/study/NCT03769987): observational registry including symptomatic neurologic disease; primary outcome death over 2 years. (NCT03769987 chunk 1) - NCT05056740 (Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic; start 2020; https://clinicaltrials.gov/study/NCT05056740): retrospective biomarker study including CSF sIL‑2R and cytokines for distinguishing NS from MS and other inflammatory disorders. (NCT05056740 chunk 1)

Expert opinion and authoritative interpretations (from sources used)

  • NCCG consensus identifies a core clinical need: standardized certainty levels and rigorous exclusion of infection/malignancy, with biopsy when feasible. (stern2018definitionandconsensus pages 1-2)
  • Contemporary reviews emphasize that randomized controlled trial evidence remains limited and management is based on expert practice patterns and retrospective evidence, motivating long-term strategy and steroid-sparing approaches. (ungprasert2022neurosarcoidosisanupdate pages 1-3, ungprasert2022neurosarcoidosisanupdate pages 9-10)

Key gaps / limitations (evidence-quality notes)

1) Diagnostic biomarkers: sIL‑2R and derived indices are promising but require larger prospective validation and standardized cutoffs (renal function effects noted). (chanpura2024diagnosticvalueof pages 6-7, chanpura2024diagnosticvalueof pages 1-2) 2) Treatment evidence: infliximab/TNF‑α inhibitor data are strong but mostly non-randomized; relapse after discontinuation suggests a need for evidence-based duration and discontinuation strategies. (sambon2022epidemiologyclinicalpresentation pages 13-14, chaiyanarm2024infliximabinneurosarcoidosis pages 6-8) 3) Population epidemiology: NS incidence/prevalence per 100,000 is not consistently reported in NS-specific literature and was not retrieved here.

Primary references used (publication date + URL)

  • Stern BJ et al. Dec 2018. JAMA Neurology. “Definition and Consensus Diagnostic Criteria for Neurosarcoidosis…” https://doi.org/10.1001/jamaneurol.2018.2295 (stern2018definitionandconsensus pages 1-2)
  • Berntsson SG et al. Apr 2023. Scientific Reports. “A comprehensive diagnostic approach in suspected neurosarcoidosis.” https://doi.org/10.1038/s41598-023-33631-z (berntsson2023acomprehensivediagnostic pages 6-7)
  • Vlad B et al. Mar 2023. Frontiers in Neurology. “Differentiating neurosarcoidosis from multiple sclerosis…” https://doi.org/10.3389/fneur.2023.1135392 (vlad2023differentiatingneurosarcoidosisfrom pages 1-2)
  • Dos Santos A et al. Sep 2024. Brain and Behavior. “Neurosarcoidosis: Clinical, biological, and MRI presentation…” https://doi.org/10.1002/brb3.3443 (santos2024neurosarcoidosisclinicalbiological pages 1-2)
  • Chanpura A et al. Aug 2024. Journal of Central Nervous System Disease. “Diagnostic value of soluble Interleukin‑2 receptor…” https://doi.org/10.1177/11795735241274186 (chanpura2024diagnosticvalueof pages 1-2)
  • Chaiyanarm S et al. Dec 2024. Annals of Clinical and Translational Neurology. “Infliximab in neurosarcoidosis: a systematic review and meta-analysis.” https://doi.org/10.1002/acn3.51968 (chaiyanarm2024infliximabinneurosarcoidosis pages 1-2)
  • Sambon P et al. Oct 2022. Frontiers in Neurology. “Epidemiology, clinical presentation, treatment, and outcome…” https://doi.org/10.3389/fneur.2022.970168 (sambon2022epidemiologyclinicalpresentation pages 1-2)
  • Ungprasert P et al. Aug 2022. Expert Review of Neurotherapeutics. “Neurosarcoidosis: an update on diagnosis and therapy.” https://doi.org/10.1080/14737175.2022.2108705 (ungprasert2022neurosarcoidosisanupdate pages 1-3)
  • Basheer M et al. Dec 2023. Life. “Neurosarcoidosis: The Presentation, Diagnosis and Treatment…” https://doi.org/10.3390/life14010069 (basheer2023neurosarcoidosisthepresentation pages 7-8)

References

  1. (stern2018definitionandconsensus pages 5-6): Barney J. Stern, Walter Royal, Jeffrey M. Gelfand, David B. Clifford, Jinny Tavee, Siddharama Pawate, Joseph R. Berger, Allen J. Aksamit, Allan Krumholz, Carlos A. Pardo, David R. Moller, Marc A. Judson, Marjolein Drent, and Robert P. Baughman. Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis consortium consensus group. JAMA Neurology, 75:1546–1553, Dec 2018. URL: https://doi.org/10.1001/jamaneurol.2018.2295, doi:10.1001/jamaneurol.2018.2295. This article has 446 citations and is from a highest quality peer-reviewed journal.

  2. (vlad2023differentiatingneurosarcoidosisfrom pages 4-5): Benjamin Vlad, Stephan Neidhart, Marc Hilty, Mario Ziegler, and Ilijas Jelcic. Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic csf parameters and mrz reaction. Frontiers in Neurology, Mar 2023. URL: https://doi.org/10.3389/fneur.2023.1135392, doi:10.3389/fneur.2023.1135392. This article has 18 citations and is from a peer-reviewed journal.

  3. (chanpura2024diagnosticvalueof pages 6-7): Aditya Chanpura, Rajesh K. Gupta, Shitiz K. Sriwastava, and Jan Rahmig. Diagnostic value of soluble interleukin-2 receptor in patients suffering neurosarcoidosis: a systematic review. Aug 2024. URL: https://doi.org/10.1177/11795735241274186, doi:10.1177/11795735241274186. This article has 7 citations and is from a peer-reviewed journal.

  4. (chaiyanarm2024infliximabinneurosarcoidosis pages 6-8): Siwakorn Chaiyanarm, Piraya Satiraphan, Natnasak Apiraksattaykul, Jiraporn Jitprapaikulsan, Weerapat Owattanapanich, Tarinee Rungjirajittranon, and Witsarut Nanthasi. Infliximab in neurosarcoidosis: a systematic review and meta‐analysis. Annals of Clinical and Translational Neurology, 11:466-476, Dec 2024. URL: https://doi.org/10.1002/acn3.51968, doi:10.1002/acn3.51968. This article has 23 citations and is from a peer-reviewed journal.

  5. (ungprasert2022neurosarcoidosisanupdate pages 1-3): Patompong Ungprasert, Persen Sukpornchairak, Brandon P Moss, Manuel L Ribeiro Neto, and Daniel A Culver. Neurosarcoidosis: an update on diagnosis and therapy. Aug 2022. URL: https://doi.org/10.1080/14737175.2022.2108705, doi:10.1080/14737175.2022.2108705. This article has 11 citations and is from a peer-reviewed journal.

  6. (basheer2023neurosarcoidosisthepresentation pages 7-8): Maamoun Basheer, Hamd Waked, Helana Jeries, Olga Azrilin, Dan Paz, Nimer Assy, Mohammad E. Naffaa, and Samih Badarny. Neurosarcoidosis: the presentation, diagnosis and treatment review of two cases. Life, 14:69, Dec 2023. URL: https://doi.org/10.3390/life14010069, doi:10.3390/life14010069. This article has 7 citations.

  7. (sambon2022epidemiologyclinicalpresentation pages 1-2): Pauline Sambon, Amina Sellimi, Alexandra Kozyreff, Olivier Gheysens, Lucie Pothen, Halil Yildiz, and Vincent van Pesch. Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: a mono-centric retrospective study and literature review. Frontiers in Neurology, Oct 2022. URL: https://doi.org/10.3389/fneur.2022.970168, doi:10.3389/fneur.2022.970168. This article has 35 citations and is from a peer-reviewed journal.

  8. (santos2024neurosarcoidosisclinicalbiological pages 1-2): Amélie Dos santos, Edouard Courtin, Aurélie Ruet, Pierre Duffau, Guillaume Mathey, Ines Bekkour, Jonathan Ciron, Laure Michel, François Xavier Blanc, Jésus Aguilar, Pascal Lejeune, Guillaume Marc, David Laplaud, Armelle Magot, Mohamed Hamidou, and Sandrine Wiertlewski. Neurosarcoidosis: clinical, biological, and mri presentation of central nervous system disease in a national multicenter cohort. Brain and Behavior, Sep 2024. URL: https://doi.org/10.1002/brb3.3443, doi:10.1002/brb3.3443. This article has 4 citations and is from a peer-reviewed journal.

  9. (santos2024neurosarcoidosisclinicalbiological pages 8-9): Amélie Dos santos, Edouard Courtin, Aurélie Ruet, Pierre Duffau, Guillaume Mathey, Ines Bekkour, Jonathan Ciron, Laure Michel, François Xavier Blanc, Jésus Aguilar, Pascal Lejeune, Guillaume Marc, David Laplaud, Armelle Magot, Mohamed Hamidou, and Sandrine Wiertlewski. Neurosarcoidosis: clinical, biological, and mri presentation of central nervous system disease in a national multicenter cohort. Brain and Behavior, Sep 2024. URL: https://doi.org/10.1002/brb3.3443, doi:10.1002/brb3.3443. This article has 4 citations and is from a peer-reviewed journal.

  10. (berntsson2023acomprehensivediagnostic pages 6-7): Shala Ghaderi Berntsson, Andreas Elmgren, Olafur Gudjonsson, Anna Grabowska, Anne-Marie Landtblom, and Maria-Francisca Moraes-Fontes. A comprehensive diagnostic approach in suspected neurosarcoidosis. Scientific Reports, Apr 2023. URL: https://doi.org/10.1038/s41598-023-33631-z, doi:10.1038/s41598-023-33631-z. This article has 38 citations and is from a peer-reviewed journal.

  11. (vlad2023differentiatingneurosarcoidosisfrom pages 9-10): Benjamin Vlad, Stephan Neidhart, Marc Hilty, Mario Ziegler, and Ilijas Jelcic. Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic csf parameters and mrz reaction. Frontiers in Neurology, Mar 2023. URL: https://doi.org/10.3389/fneur.2023.1135392, doi:10.3389/fneur.2023.1135392. This article has 18 citations and is from a peer-reviewed journal.

  12. (sambon2022epidemiologyclinicalpresentation pages 14-16): Pauline Sambon, Amina Sellimi, Alexandra Kozyreff, Olivier Gheysens, Lucie Pothen, Halil Yildiz, and Vincent van Pesch. Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: a mono-centric retrospective study and literature review. Frontiers in Neurology, Oct 2022. URL: https://doi.org/10.3389/fneur.2022.970168, doi:10.3389/fneur.2022.970168. This article has 35 citations and is from a peer-reviewed journal.

  13. (vlad2023differentiatingneurosarcoidosisfrom pages 2-3): Benjamin Vlad, Stephan Neidhart, Marc Hilty, Mario Ziegler, and Ilijas Jelcic. Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic csf parameters and mrz reaction. Frontiers in Neurology, Mar 2023. URL: https://doi.org/10.3389/fneur.2023.1135392, doi:10.3389/fneur.2023.1135392. This article has 18 citations and is from a peer-reviewed journal.

  14. (sinha2024neurosarcoidosiscurrentperspectives pages 4-6): Tanya Sinha, Sohaira Tahir, FNU Namal, FNU Vineesha, FNU Warsha, Zeeshan Ahmed, Syed Faqeer Hussain Bokhari, Muhammad Haris, and Muhammad Mudasser Khan. Neurosarcoidosis: current perspectives on diagnosis, management, and future directions. Cureus, Sep 2024. URL: https://doi.org/10.7759/cureus.69208, doi:10.7759/cureus.69208. This article has 9 citations.

  15. (chanpura2024diagnosticvalueof pages 1-2): Aditya Chanpura, Rajesh K. Gupta, Shitiz K. Sriwastava, and Jan Rahmig. Diagnostic value of soluble interleukin-2 receptor in patients suffering neurosarcoidosis: a systematic review. Aug 2024. URL: https://doi.org/10.1177/11795735241274186, doi:10.1177/11795735241274186. This article has 7 citations and is from a peer-reviewed journal.

  16. (vlad2023differentiatingneurosarcoidosisfrom pages 1-2): Benjamin Vlad, Stephan Neidhart, Marc Hilty, Mario Ziegler, and Ilijas Jelcic. Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic csf parameters and mrz reaction. Frontiers in Neurology, Mar 2023. URL: https://doi.org/10.3389/fneur.2023.1135392, doi:10.3389/fneur.2023.1135392. This article has 18 citations and is from a peer-reviewed journal.

  17. (chaiyanarm2024infliximabinneurosarcoidosis pages 1-2): Siwakorn Chaiyanarm, Piraya Satiraphan, Natnasak Apiraksattaykul, Jiraporn Jitprapaikulsan, Weerapat Owattanapanich, Tarinee Rungjirajittranon, and Witsarut Nanthasi. Infliximab in neurosarcoidosis: a systematic review and meta‐analysis. Annals of Clinical and Translational Neurology, 11:466-476, Dec 2024. URL: https://doi.org/10.1002/acn3.51968, doi:10.1002/acn3.51968. This article has 23 citations and is from a peer-reviewed journal.

  18. (chaiyanarm2024infliximabinneurosarcoidosis pages 2-3): Siwakorn Chaiyanarm, Piraya Satiraphan, Natnasak Apiraksattaykul, Jiraporn Jitprapaikulsan, Weerapat Owattanapanich, Tarinee Rungjirajittranon, and Witsarut Nanthasi. Infliximab in neurosarcoidosis: a systematic review and meta‐analysis. Annals of Clinical and Translational Neurology, 11:466-476, Dec 2024. URL: https://doi.org/10.1002/acn3.51968, doi:10.1002/acn3.51968. This article has 23 citations and is from a peer-reviewed journal.

  19. (sambon2022epidemiologyclinicalpresentation pages 13-14): Pauline Sambon, Amina Sellimi, Alexandra Kozyreff, Olivier Gheysens, Lucie Pothen, Halil Yildiz, and Vincent van Pesch. Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: a mono-centric retrospective study and literature review. Frontiers in Neurology, Oct 2022. URL: https://doi.org/10.3389/fneur.2022.970168, doi:10.3389/fneur.2022.970168. This article has 35 citations and is from a peer-reviewed journal.

  20. (NCT04911348 chunk 1): Neurosarcoidosis : Initial Presentation and Disease Course. Central Hospital, Nancy, France. 2021. ClinicalTrials.gov Identifier: NCT04911348

  21. (NCT02920710 chunk 1): ACTHAR Therapy for Central Nervous System Sarcoidosis. The Cleveland Clinic. 2019. ClinicalTrials.gov Identifier: NCT02920710

  22. (NCT03769987 chunk 1): Robert P Baughman. Registry for Advanced Sarcodiosis. University of Cincinnati. 2017. ClinicalTrials.gov Identifier: NCT03769987

  23. (NCT05056740 chunk 1): Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic. Centre Hospitalier Universitaire de Nice. 2020. ClinicalTrials.gov Identifier: NCT05056740

  24. (stern2018definitionandconsensus pages 1-2): Barney J. Stern, Walter Royal, Jeffrey M. Gelfand, David B. Clifford, Jinny Tavee, Siddharama Pawate, Joseph R. Berger, Allen J. Aksamit, Allan Krumholz, Carlos A. Pardo, David R. Moller, Marc A. Judson, Marjolein Drent, and Robert P. Baughman. Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis consortium consensus group. JAMA Neurology, 75:1546–1553, Dec 2018. URL: https://doi.org/10.1001/jamaneurol.2018.2295, doi:10.1001/jamaneurol.2018.2295. This article has 446 citations and is from a highest quality peer-reviewed journal.

  25. (berntsson2023acomprehensivediagnostic media 360bc208): Shala Ghaderi Berntsson, Andreas Elmgren, Olafur Gudjonsson, Anna Grabowska, Anne-Marie Landtblom, and Maria-Francisca Moraes-Fontes. A comprehensive diagnostic approach in suspected neurosarcoidosis. Scientific Reports, Apr 2023. URL: https://doi.org/10.1038/s41598-023-33631-z, doi:10.1038/s41598-023-33631-z. This article has 38 citations and is from a peer-reviewed journal.

  26. (berntsson2023acomprehensivediagnostic media bbaa5c3a): Shala Ghaderi Berntsson, Andreas Elmgren, Olafur Gudjonsson, Anna Grabowska, Anne-Marie Landtblom, and Maria-Francisca Moraes-Fontes. A comprehensive diagnostic approach in suspected neurosarcoidosis. Scientific Reports, Apr 2023. URL: https://doi.org/10.1038/s41598-023-33631-z, doi:10.1038/s41598-023-33631-z. This article has 38 citations and is from a peer-reviewed journal.

  27. (berntsson2023acomprehensivediagnostic media 2e1b352e): Shala Ghaderi Berntsson, Andreas Elmgren, Olafur Gudjonsson, Anna Grabowska, Anne-Marie Landtblom, and Maria-Francisca Moraes-Fontes. A comprehensive diagnostic approach in suspected neurosarcoidosis. Scientific Reports, Apr 2023. URL: https://doi.org/10.1038/s41598-023-33631-z, doi:10.1038/s41598-023-33631-z. This article has 38 citations and is from a peer-reviewed journal.

  28. (ungprasert2022neurosarcoidosisanupdate pages 9-10): Patompong Ungprasert, Persen Sukpornchairak, Brandon P Moss, Manuel L Ribeiro Neto, and Daniel A Culver. Neurosarcoidosis: an update on diagnosis and therapy. Aug 2022. URL: https://doi.org/10.1080/14737175.2022.2108705, doi:10.1080/14737175.2022.2108705. This article has 11 citations and is from a peer-reviewed journal.

  29. (basheer2023neurosarcoidosisthepresentation pages 6-7): Maamoun Basheer, Hamd Waked, Helana Jeries, Olga Azrilin, Dan Paz, Nimer Assy, Mohammad E. Naffaa, and Samih Badarny. Neurosarcoidosis: the presentation, diagnosis and treatment review of two cases. Life, 14:69, Dec 2023. URL: https://doi.org/10.3390/life14010069, doi:10.3390/life14010069. This article has 7 citations.

Artifacts

OpenScientist ▸
1. Disease Information
openscientist-autonomous 85 citations 2026-05-16T06:53:11.461656

1. Disease Information

Overview

Neurosarcoidosis (NS) is a granulomatous inflammatory disease affecting the central nervous system (CNS) and/or peripheral nervous system (PNS), occurring as a manifestation of systemic sarcoidosis. It is characterized by the formation of noncaseating epithelioid granulomas in neural tissue, meninges, cranial nerves, spinal cord, and peripheral nerves. NS can present as the initial manifestation of sarcoidosis or develop in the setting of known systemic disease PMID: 39398844, PMID: 34607912.

Key Identifiers

Database Identifier
MONDO MONDO:0019203 (neurosarcoidosis)
ICD-10 D86.89 (Sarcoidosis of other sites) / G53.2 (Cranial nerve disorders in sarcoidosis)
ICD-11 4B20.Y (Sarcoidosis of other or unspecified sites, nervous system)
MeSH D009492 (Neurosarcoidosis); broader: D012507 (Sarcoidosis)
OMIM 181000 (Sarcoidosis, susceptibility to)
Orphanet ORPHA:797 (Sarcoidosis)
SNOMED CT 230193001 (Neurosarcoidosis)
GARD 7122 (Sarcoidosis)

Synonyms and Alternative Names

  • Neurosarcoidosis
  • Nervous system sarcoidosis
  • CNS sarcoidosis
  • Neuro-sarcoid
  • Sarcoid neuropathy (peripheral form)
  • Heerfordt syndrome (uveoparotid fever variant with cranial nerve involvement)

Data Source Type

Information is derived from aggregated disease-level resources (published literature, disease registries, clinical cohort studies, GWAS databases) rather than individual patient-level EHR data.

2. Etiology

Disease Causal Factors

Neurosarcoidosis is a multifactorial disease whose exact etiology remains incompletely understood. The prevailing model posits that genetically predisposed individuals develop an exaggerated granulomatous immune response upon exposure to one or more environmental antigens. As stated in a comprehensive review: "The pathogenesis involves immune dysregulation in genetically predisposed individuals exposed to environmental antigens, with granuloma formation as the hallmark" PMID: 41429672.

Genetic Risk Factors

Sarcoidosis has a strong genetic component, with heritability estimated at 60–70% in twin and family studies PMID: 30587386. Genome-wide association studies have identified multiple susceptibility loci:

HLA Region (Chromosome 6p21): - HLA-DRB1 (HGNC:4948): Strongest association; 49 SNPs in the HLA region (HLA-DRA, DRB9, DRB5, DQA1, BRD2) significantly associated with sarcoidosis in European Americans. Classical alleles DRB10101, DQA10101, DQB10501 confer susceptibility; DRB103 associated with disease resolution (OR 0.35; P < 0.01) PMID: 37399103, PMID: 27662826. - BTNL2 (HGNC:1142): rs2076530 G>A, OR 1.32–1.60 across populations PMID: 26164297. - NOTCH4 (HGNC:7884): Genome-wide significance in African Americans (rs715299, P = 6.51 x 10^-10) PMID: 22952805.

Non-HLA Loci: - ANXA11 (HGNC:543): rs1049550 C>T, OR 1.21–1.62; confirmed across multiple ethnicities PMID: 26164297. - IL23R (HGNC:19100): rs11209026 G>A; implicates Th17 pathway PMID: 32826979. - IL12B (HGNC:5970), NFKB1 (HGNC:7794), SH2B3 (HGNC:29605), FAM117B: Four novel loci at genome-wide significance in Europeans PMID: 26051272. - CCL24 (HGNC:10621), STYXL1-SRRM3, C1orf141-IL23R: Identified in Japanese cohort PMID: 32826979. - XAF1 (HGNC:28915): Identified via admixture mapping in African Americans; immunohistochemistry showed lack of XAF1 expression with high XIAP expression in sarcoidosis granulomas, implicating the apoptosis pathway in granuloma maintenance PMID: 24663488. - NOD2 (HGNC:5331): Mutations cause Blau syndrome (early-onset sarcoidosis); NOD2 activates NF-kB pathway upon MDP binding PMID: 32618442. - RAB23 (HGNC:14431): Genetic variants associated with sarcoidosis uveitis PMID: 29416296.

Sex-dependent genetic variations in the MHC region have been demonstrated, with distinct associations in Lofgren's vs. non-Lofgren's phenotypes between male and female patients PMID: 37250650.

Environmental Risk Factors

The ACCESS (A Case Control Etiologic Study of Sarcoidosis) case-control study (706 patients, 706 controls) identified: - Insecticide exposure: OR 1.52 (95% CI 1.01–2.28) - Musty odors at work: OR 1.62 (95% CI 1.24–2.11) - Agricultural employment: OR 1.46 (95% CI 0.98–2.18) - Positive smoking history: Protective, OR 0.62 (95% CI 0.50–0.77)

PMID: 15347561

World Trade Center dust exposure dramatically increased sarcoidosis incidence (25 per 100,000) among firefighters, with prominent extrathoracic involvement PMID: 29066387.

Suspected Infectious Triggers

  • Mycobacterium spp.: Mycobacterial DNA and antigens detected in sarcoidosis granulomas; mycobacterial catalase-peroxidase (mKatG) serves as a candidate sarcoidosis antigen PMID: 32676081.
  • Cutibacterium (Propionibacterium) acnes: Used to establish animal models of sarcoidosis; implicated as an endogenous antigen trigger PMID: 39826790.

Protective Factors

  • HLA-DRB1*03 allele: Associated with disease resolution (21.2% in resolving vs. 4.9% in chronic disease; RR 0.35) PMID: 27662826.
  • Smoking: Paradoxically protective (OR 0.62) PMID: 15347561.

Gene-Environment Interactions

Sarcoidosis is a paradigmatic gene-environment interaction disease. HLA alleles determine antigen presentation capacity, influencing the granulomatous response to inhaled environmental or microbial antigens. Epigenetic mechanisms (DNA methylation, histone modifications) mediate environmental exposure effects on gene expression in sarcoidosis PMID: 34168064, PMID: 24242359.

3. Phenotypes

Cranial Neuropathies

  • Frequency: Most common presentation; 47.9% in Indian cohort, ~50% overall
  • Facial nerve palsy (HP:0010628): Most frequent; bilateral in ~30%
  • Optic neuropathy (HP:0000618): 14.6–25%; perineural enhancement pattern on MRI predicts better visual outcomes; 44.4% have poor visual outcomes (VA of 20/100 or worse) PMID: 40023555
  • Lower cranial nerve palsies: Vagus (dysphagia), vestibulocochlear (hearing loss)
  • Severity: Variable; onset adult (median age 42 years)
  • QoL impact: Significant disability from visual loss, facial disfigurement
  • HPO terms: HP:0001291 (Cranial nerve palsy), HP:0000618 (Optic neuropathy), HP:0010628 (Facial palsy)

Meningeal Disease

  • Leptomeningeal enhancement: 47% of NS patients
  • Pachymeningeal enhancement: 32%
  • Chronic aseptic meningitis (HP:0001311)
  • Frequency: Among the most common manifestations
  • HPO terms: HP:0001311 (Abnormality of the meninges), HP:0100310 (Leptomeningeal enhancement)

Myelopathy (Spinal Cord Sarcoidosis)

  • Frequency: 25% of NS presentations
  • Prognosis: Unfavorable; 47.4% with loss of autonomy (Rankin score of 2 or greater) at last follow-up after median 7.8 years
  • Prognostic factors: Gadolinium enhancement (protective, RR 0.61), meningeal involvement (adverse, RR 2.05), CSF cell count (adverse, RR 1.16 per log increase)
  • TNF-alpha antagonists: Significantly decreased relapse/progression rate vs. corticosteroids alone (RR 0.33, 95% CI 0.11–0.98) PMID: 35145013
  • HPO terms: HP:0001258 (Spastic paraplegia), HP:0003470 (Myelopathy)

Hypothalamic-Pituitary Involvement

  • Frequency: 26% in imaging series; diabetes insipidus prevalence 54.5% in sellar/parasellar NS lesions PMID: 33769630
  • Endocrine dysfunction: Gonadotropin deficiency 88.8%, TSH deficiency 67.4%, GH deficiency 50%, ACTH deficiency 48.8%, hyperprolactinemia 48.8%, diabetes insipidus 65.2% PMID: 22753675
  • Reversibility: Only 13% of patients recover hormonal function after treatment; MRI findings may improve, but endocrine defects are largely irreversible
  • HPO terms: HP:0000871 (Panhypopituitarism), HP:0000873 (Diabetes insipidus), HP:0000823 (Central hypothyroidism)

Seizures and Parenchymal Disease

  • Non-enhancing white matter (NEWM) lesions: Most common imaging abnormality (56%)
  • Parenchymal granulomas: 27%
  • Seizures: Can be initial presentation, particularly in pediatric cases PMID: 23685039
  • HPO terms: HP:0001250 (Seizure), HP:0002352 (Leukoencephalopathy)

Hydrocephalus

  • Frequency: Uncommon but serious complication
  • Mechanism: Granulomatous inflammation obstructing CSF flow
  • HPO terms: HP:0000238 (Hydrocephalus)

Small Fiber Neuropathy (SFN)

  • Prevalence: 33–86% in sarcoidosis patients PMID: 41218636
  • Symptoms: Pain, numbness, burning, autonomic dysfunction (GI dysmotility, palpitations, sexual dysfunction)
  • Diagnosis: Clinical signs + normal NCS + abnormal QST or decreased intraepidermal nerve fiber density (IENFD) on skin biopsy
  • Length-dependent and non-length-dependent patterns reported
  • HPO terms: HP:0009830 (Peripheral neuropathy), HP:0012534 (Small fiber neuropathy)

Fatigue and Cognitive Impairment

  • Fatigue: Extremely prevalent; everyday cognitive failure and depressive symptoms are strongest predictors PMID: 29239767
  • Cognitive impairment: Prevalence 0–35%; mechanisms include BBB disruption, cytokine-driven neuroinflammation (IL-6, TNF-alpha, IFN-gamma), cerebral hypoperfusion PMID: 40769406
  • Disability impact: 43% of Dutch sarcoidosis patients undergoing disability evaluation had significantly more extrapulmonary symptoms, severe fatigue, reduced exercise capacity, memory and concentration problems PMID: 31101981
  • HPO terms: HP:0012378 (Fatigue), HP:0100543 (Cognitive impairment)

4. Genetic/Molecular Information

Susceptibility Gene Table

Gene HGNC ID Key Variant OR Population PMID
HLA-DRB1 4948 Multiple classical alleles 1.5–3.5 Multi-ethnic 37399103
BTNL2 1142 rs2076530 G>A 1.32–1.60 Multi-ethnic 26164297
ANXA11 543 rs1049550 C>T 1.21–1.62 Multi-ethnic 26164297
NOTCH4 7884 rs715299 GW-sig African American 22952805
IL23R 19100 rs11209026 G>A GW-sig Japanese 32826979
IL12B 5970 rs4921492 GW-sig European 26051272
NFKB1 7794 rs223498 GW-sig European 26051272
SH2B3 29605 rs653178 GW-sig European 26051272
CCL24 10621 — GW-sig Japanese 32826979
XAF1 28915 rs6502976 9.5x10^-6 African American 24663488
NOD2 5331 Blau mutations Mendelian Multi-ethnic 32618442
RAB23 14431 rs1040461 Sig Multi-ethnic 29416296
HLA-DPB1 4940 Multiple GW-sig European 26051272
HLA-DRA 4947 rs74318745 9.4x10^-11 African American 24663488

GW-sig = genome-wide significant

Inheritance Pattern

Sarcoidosis follows a multifactorial/polygenic inheritance pattern. The pooled familial prevalence is 9.5% (CI 4.6–16.1%), highest in French, African American, Dutch, and Irish populations. Relative risk for first-degree relatives differs between European Americans (OR 16.6) and African Americans (OR 3.1) PMID: 30587386.

Epigenetic Information

Epigenetic modifications are emerging as important regulators in sarcoidosis. DNA methylation changes have been identified in immune cells from sarcoidosis patients. Histone modifications and microRNA dysregulation alter transcriptional activity of genes involved in Th1/Th17 differentiation and fibroblast activation. Epigenetics mediates the interaction between environmental exposures and genetic susceptibility PMID: 34168064, PMID: 24242359.

5. Environmental Information

Environmental and Occupational Factors

Exposure Effect Evidence
Insecticide exposure Risk, OR 1.52 (1.01–2.28) ACCESS study, PMID: 15347561
Musty odors at work Risk, OR 1.62 (1.24–2.11) ACCESS study, PMID: 15347561
Agricultural employment Risk, OR 1.46 (0.98–2.18) ACCESS study, PMID: 15347561
World Trade Center dust Risk, incidence 25/100,000 PMID: 29066387
Metal dusts (beryllium) Risk (chronic beryllium disease) PMID: 32256501
Smoking Protective, OR 0.62 (0.50–0.77) ACCESS study, PMID: 15347561

Infectious Agents

  • Mycobacterium tuberculosis and NTM (NCBI Taxon: 1773): DNA and antigens (mKatG) detected in granulomas
  • Cutibacterium acnes (NCBI Taxon: 1747): Used in animal models; endogenous trigger candidate
  • Both organisms represent "poorly degradable antigens" consistent with the pathogenic model PMID: 32676081

6. Mechanism / Pathophysiology

Causal Chain: From Trigger to Granuloma

The pathogenesis of neurosarcoidosis follows a multi-step cascade:

Environmental/Microbial Antigen
|
v
Antigen Presentation via HLA Class II (DRB1) on APCs
|
v
CD4+ T Cell Activation --> Th1/Th17 Polarization
|
v
Cytokine Release: IL-2, IL-12, IL-18, TNF-alpha, IFN-gamma (Th1)
           IL-17, IL-23 (Th17)
|
v
Macrophage Recruitment & Activation (M1 --> M2-like)
|
v
JAK-STAT Signaling --> Granuloma Expansion
mTOR Activation --> Lipid Droplet Formation in Macrophages
|
v
Non-caseating Granuloma Formation in Neural Tissue
|
v
CD47/SIRPalpha Interaction (Th17.1 <-> Macrophage)
--> Impaired Antigen Clearance --> Disease Progression
|
v
Neural Compression, Ischemia, Demyelination, Fibrosis
|
v
Clinical Manifestations

Key Molecular Pathways

  1. TNF-alpha/IFN-gamma Axis (GO:0006955 immune response): Central to granuloma initiation; "An abnormal T regulatory response, in parallel with an enhanced Th1 response, results in the release of cytokines, including IL-2, IL-12, IL-18, tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma), which initiates granuloma formation" PMID: 41054684.

  2. JAK-STAT Pathway (GO:0007259): "Enhanced Th17 production stimulates the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway, ultimately leading to granuloma expansion" PMID: 41054684.

  3. mTOR Signaling (GO:0031929): Beta-c cytokines regulate macrophage activation; "CSL311 inhibited hyperactivation of mTOR signaling and reduced lipid droplet formation in granuloma macrophages" PMID: 41476976.

  4. PI3K/AKT Pathway (GO:0043491): Anti-TL1A monoclonal antibody attenuates granuloma formation by inhibiting the downstream PI3K/AKT signaling pathway PMID: 38852524.

  5. TLR4/MyD88/NF-kB (GO:0002224): Mediates macrophage differentiation into M1-type and CD4+ T cell differentiation into Th1/Th17 cells PMID: 39951973.

  6. CD47/SIRPalpha Interaction (GO:0002682): "Th17.1 cells impaired the antigen phagocytic and processing ability of macrophages through CD47/SIRPalpha interaction. Blockade of CD47/SIRPalpha interaction significantly repressed the progression of sarcoidosis" PMID: 41316274.

  7. XAF1/XIAP Apoptosis Pathway (GO:0043066): Lack of XAF1 expression with high XIAP in granulomas suggests resistance to apoptosis maintains granulomas PMID: 24663488.

Cell Types Involved

Cell Type CL Term Role
CD4+ T helper 1 cell CL:0000545 IFN-gamma, IL-2 production; granuloma initiation
Th17 cell CL:0000899 IL-17 production; granuloma expansion
Th17.1 cell CL:0002043 Impairs macrophage phagocytosis via CD47/SIRPalpha
Alveolar macrophage CL:0000583 Granuloma core; antigen presentation
M2-like macrophage CL:0000235 Fibrosis; lipid accumulation
Regulatory T cell CL:0000815 Defective regulation in sarcoidosis
Dendritic cell CL:0000451 Antigen presentation; MyD88-dependent lung trafficking
Neutrophil CL:0000775 NETs in progressive disease; association with fibrosis
B cell CL:0000236 Reduced in BAL; role in lung protection

Metabolic Changes

Aberrant lipid metabolism in granuloma macrophages is a newly recognized feature. MALDI-MSI reveals shared lipid signatures in sarcoid-like granulomas, with mTOR-driven lipid droplet formation in macrophages representing a therapeutic target PMID: 38353578, PMID: 40668560.

Dysregulated vitamin D metabolism is characteristic: extrarenal 1alpha-hydroxylase (CYP27B1) expression by granuloma macrophages leads to uncontrolled 1,25-(OH)2D3 production, causing hypercalcemia (1.8%) and hypercalciuria (18.8–26%) PMID: 11158062, PMID: 32114588.

Molecular Profiling

Single-cell transcriptomics: Five macrophage subpopulations identified in BAL (resident, high-MT resident, recruited, profibrotic recruited, proliferating) with distinct gene expression profiles. Significant reduction in B cells in sarcoidosis vs. controls. Specific cell-to-cell communication alterations between macrophages and T cells PMID: 39896662.

Spatial transcriptomics/immune mapping: Granulomas from TB and sarcoidosis show distinct immunological microenvironments PMID: 38385142.

Neutrophil involvement: Neutrophil gene signatures enriched in progressive sarcoidosis; extracellular vimentin promotes neutrophil-dominant granulomatous inflammation with NETosis as a potential therapeutic target PMID: 42084847.

7. Anatomical Structures Affected

Organ Level

Primary organs directly affected: - Brain (UBERON:0000955): Parenchymal granulomas, white matter lesions - Spinal cord (UBERON:0002240): Myelopathy, 25% of NS - Cranial nerves (UBERON:0001785): 30–50% of NS - Meninges (UBERON:0002360): Leptomeningeal (47%), pachymeningeal (32%) - Hypothalamus/Pituitary (UBERON:0001898/UBERON:0000007): 26% of NS

Secondary organ involvement: - Lungs (UBERON:0002048): 96% of sarcoidosis patients have pulmonary involvement - Heart (UBERON:0000948): 12% of NS patients also have cardiac sarcoidosis PMID: 38181319 - Eyes (UBERON:0000970): Uveitis in 12% - Skin (UBERON:0002097): 23% cutaneous involvement - Kidneys (UBERON:0002113): 3% renal involvement

Tissue and Cell Level

  • Nervous tissue (UBERON:0003714): Primary target
  • Meningeal tissue (UBERON:0002360): Leptomeninges and pachymeninges
  • Lymphoid tissue (UBERON:0001744): Granuloma formation in lymph nodes
  • Endocrine tissue: Pituitary gland, hypothalamus

Subcellular Level

  • Lysosomes (GO:0005764): ACE and chitotriosidase production
  • Mitochondria (GO:0005739): mTOR signaling regulation
  • Lipid droplets (GO:0005811): Aberrant formation in granuloma macrophages
  • Cell surface (GO:0009986): CD47/SIRPalpha interactions

Localization

CNS involvement patterns from 100 NS patients PMID: 32703543:

Location Frequency
Non-enhancing white matter lesions 56%
Leptomeningeal enhancement 47%
Pachymeningeal enhancement 32%
Cranial nerve enhancement 30%
Parenchymal granulomas 27%
Hypothalamic-pituitary region 26%

Lateralization is typically bilateral but can be asymmetric. Spinal cord involvement most commonly affects the cervical and thoracic segments.

8. Temporal Development

Onset

  • Typical age: Median 42 years (IQR 32–53); bimodal distribution with peaks at 25–35 and 45–65 years
  • Pediatric NS: Exceptionally rare; seizures more common presenting feature than in adults PMID: 23685039, PMID: 10207931
  • Onset pattern: Subacute to chronic; HP involvement precedes sarcoidosis diagnosis in 54% of cases PMID: 22753675

Progression

  • Disease course: Relapsing-remitting or chronic progressive
  • Relapse rate: 56% upon infliximab discontinuation PMID: 29030454; 48% in renal sarcoidosis during corticosteroid taper
  • Spinal cord: Mean relapse/progression rate 0.17 per person-year, decreasing over time PMID: 35145013
  • Disease duration: Chronic lifelong in most; spontaneous resolution rare in NS

Remission Patterns

  • Spontaneous remission: Uncommon in neurosarcoidosis (unlike pulmonary sarcoidosis)
  • Treatment-induced remission: Achievable but frequently relapsing upon treatment taper
  • Endocrine deficits: Largely irreversible even with treatment PMID: 22753675

9. Inheritance and Population

Epidemiology

Metric Value Source
Sarcoidosis prevalence (US) 10–60 per 100,000 PMID: 15925652
NS prevalence (estimated) ~1 per 100,000 PMID: 18977817
NS frequency among sarcoidosis 5–15% Multiple sources
NS in Spanish cohort 5.5% (85/1532) PMID: 34215779

Population Demographics

  • Sex ratio: Female predominance at 50–63% across cohorts
  • Racial disparity: African Americans disproportionately affected with higher incidence, more severe disease, and more frequent elevated ESR (62% vs. 24%, P = 0.005); lower radiographic resolution (14% vs. 41%, P = 0.017) PMID: 32771711
  • Geographic distribution: Worldwide; higher incidence in Northern European countries (especially Scandinavia), African Americans in the US, and West Indian immigrants in the UK
  • Familial risk: First-degree relative OR 3.1 (African Americans) to 16.6 (European Americans) PMID: 30587386

10. Diagnostics

Diagnostic Criteria

The 2018 Neurosarcoidosis Consortium Consensus Group criteria (Stern criteria) PMID: 30167654:

Classification Definition
Definite Compatible clinical/MRI presentation + neural tissue biopsy showing noncaseating granulomas + exclusion of other causes
Probable Compatible clinical/MRI presentation + extraneural biopsy showing noncaseating granulomas + exclusion of other causes
Possible Compatible clinical/MRI presentation without histopathological confirmation + exclusion of other causes

Imaging

  • MRI (gold standard): Gadolinium-enhanced MRI reveals leptomeningeal, pachymeningeal, cranial nerve, parenchymal, and spinal cord enhancement patterns
  • Medullary vein sign on SWI: Sensitivity 71.4%, specificity 92.3% PMID: 35997361
  • FDG-PET/CT: Useful for detecting occult systemic disease, monitoring treatment response; may reveal pathology when MRI is normal PMID: 38268056, PMID: 19755199

CSF Analysis

Parameter NS Finding Discriminating Power
Lymphocytic pleocytosis 63% WCC >30/uL favors NS over MS
Elevated protein 62% Albumin quotient elevated in NS
CSF-ACE Sensitivity 55%, specificity 94% at cutoff 8 nmol/mL/min PMID: 12405488
Oligoclonal bands Only 3% in NS Powerful discriminator from MS (>95%)
sIL-2R Elevated Differentiates from MS and vasculitis
NfL Significantly elevated Correlates with MRI inflammation

PMID: 32354749, PMID: 37034091, PMID: 39193252, PMID: 33672795

Serum Biomarkers

  • ACE: Traditional but poor sensitivity/specificity; elevated in only 51% of NS, 14% of isolated NS PMID: 32354749
  • sIL-2R: Superior to ACE for monitoring; Se 52–82%, Sp 57–94%
  • Chitotriosidase: Sp 85%; combined ACE x CTO "double product" achieves AUC 0.898 PMID: 31672631
  • NfL (plasma): Correlates with CNS inflammation extent PMID: 33672795

Biopsy

  • Neural tissue biopsy: Required for definite diagnosis; rarely performed due to morbidity
  • Extraneural biopsy: Mediastinal lymph node, skin, liver—establishes probable NS
  • Minor salivary gland biopsy: Sensitivity only 7.7%, specificity 100%; should be reserved for selected cases PMID: 36858037

Differential Diagnosis

Key conditions to exclude: - Multiple sclerosis (OCBs present in >95% of MS vs. 3% NS) - Lymphoma / CNS neoplasms - Tuberculosis / fungal meningitis - Neuromyelitis optica spectrum disorder - IgG4-related disease - Granulomatosis with polyangiitis - Histiocytic disorders (LCH, ECD) - VEXAS syndrome

Genetic Testing

Not routinely recommended. HLA typing may have prognostic value (DRB1*03 leads to favorable prognosis). No clinical genetic tests specific to neurosarcoidosis exist, though familial sarcoidosis evaluation may be warranted.

11. Outcome/Prognosis

Survival

  • 10-year survival: 89% (95% CI 84–94%) PMID: 29052709
  • In-hospital mortality: 3.9% for emergency sarcoidosis admissions; 2-year transplant-free survival 86.8% PMID: 39209060
  • Infliximab-treated cohort mortality: 18% at median 32 months, reflecting disease severity PMID: 32718952

Morbidity and Function

  • Spinal cord sarcoidosis: 47.4% loss of autonomy (Rankin score 2 or greater) PMID: 35145013
  • Optic neuropathy: 44.4% with poor visual outcomes PMID: 40023555
  • Hypothalamic-pituitary: Endocrine recovery in only 13% of patients PMID: 22753675
  • Fatigue: Major contributor to disability; 43% of patients undergo disability evaluation PMID: 31101981

Prognostic Factors

Favorable: - DRB1*03 allele - Perineural optic enhancement pattern on MRI - Gadolinium enhancement in spinal cord (indicates active, potentially reversible disease) - Early treatment initiation

Unfavorable: - African American race - Definite NS classification - Meningeal involvement in spinal cord disease - Bilateral optic neuritis - High CSF cell count - Relapsing disease course

Prognostic Biomarkers

  • NfL: Correlates with MRI inflammatory activity; "NFL levels in cerebrospinal fluid and plasma are significantly higher in neurosarcoidosis patients compared to extra-neurologic patients and healthy controls, and the levels correlate to the extent of inflammation on MRI" PMID: 33672795
  • Chitotriosidase: Best specificity (85%) among traditional biomarkers for monitoring PMID: 30944672
  • sIL-2R: Valuable for detecting extrapulmonary involvement PMID: 41213628

12. Treatment

Pharmacotherapy

First-line: Corticosteroids (MAXO:0000015 glucocorticoid therapy)

  • Prednisone/prednisolone: Standard initial therapy (91% of patients); doses of 0.5–1 mg/kg/day
  • High-dose (40 mg) not superior to lower dose (20 mg) in pulmonary sarcoidosis, with similar relapse rates PMID: 37690784
  • Dexamethasone: Used for acute severe manifestations
  • ATC: H02AB06 (prednisolone), H02AB07 (prednisone)

Second-line: Steroid-Sparing Immunosuppressants (MAXO:0000601 immunosuppressive therapy)

  • Methotrexate (ATC: L01BA01): More effective than azathioprine for spinal cord sarcoidosis (RR 2.83 for azathioprine relapse vs. methotrexate) PMID: 35145013
  • Mycophenolate mofetil (ATC: L04AA06): Used as steroid-sparing agent; mixed evidence
  • Azathioprine (ATC: L04AX01): Inferior to methotrexate in spinal cord NS
  • Cyclophosphamide (ATC: L01AA01): Used for severe refractory cases; 56% relapse rate, inferior to infliximab PMID: 40702280

Third-line: TNF-alpha Inhibitors (MAXO:0001298 biologic therapy)

  • Infliximab (ATC: L04AB02): Most extensively studied; MRI improvement in 82.1% (complete remission 51.8%, partial 30.1%); clinical improvement in 77.3%; relapse rate 6% vs. 56% cyclophosphamide vs. 38% methotrexate (p = 0.06); corticosteroid tapering in 68% PMID: 29030454, PMID: 40702280, PMID: 32718952
  • Infliximab biosimilar: Comparable efficacy and safety PMID: 30739183
  • Adalimumab (ATC: L04AB04): 8/10 NS patients responded clinically and radiographically PMID: 38640580

Emerging Therapies

  • JAK inhibitors (tofacitinib, baricitinib, ruxolitinib): JAK-STAT pathway inhibition; clinical updates show promise in cutaneous granulomatous diseases PMID: 41459541, PMID: 35510170
  • Anti-TL1A monoclonal antibody: Inhibits PI3K/AKT; reduces Th1/Th17 dysregulation in preclinical models PMID: 38852524
  • CSL311 (beta-c receptor antagonist): Mitigates mTOR signaling and lipid droplet formation in granuloma macrophages PMID: 41476976
  • Anti-CD47/SIRPalpha: Blockade represses sarcoidosis progression in preclinical models PMID: 41316274
  • mTOR inhibitors: Potential based on mechanistic data PMID: 41651390
  • Rituximab (ATC: L01FA01): Limited efficacy in NS PMID: 32404428
  • IL-6 inhibitors (tocilizumab): Accepted in critical care settings PMID: 41371265

Surgical and Interventional

  • CSF diversion (ventriculoperitoneal shunt): For hydrocephalus
  • Neurosurgical biopsy: Diagnostic; rarely therapeutic
  • Radiation therapy: Rarely used; reserved for refractory focal lesions

Supportive and Rehabilitative

  • Hormone replacement therapy (MAXO:0000780): Essential for hypothalamic-pituitary NS with irreversible endocrinopathies
  • Desmopressin (ATC: H01BA02): For diabetes insipidus
  • Exercise training: RCT evidence supports cycling programs for reducing fatigue and improving QoL PMID: 41015397
  • Pulmonary rehabilitation: Improves exercise tolerance at 6 and 12 months PMID: 31855785
  • Online mindfulness-based cognitive therapy (eMBCT): Significant fatigue reduction (FAS change -4.53 vs. -1.28; between-group difference 3.26, P = 0.0025) plus improvement in anxiety, depression, and health status PMID: 36427515

Treatment Strategy

Neurosarcoidosis Treatment Algorithm:

Step 1: High-dose corticosteroids (prednisone 0.5-1 mg/kg/day)
   | [inadequate response or relapse on taper]
   v
Step 2: Add steroid-sparing agent (methotrexate preferred > azathioprine)
   | [refractory disease]
   v
Step 3: TNF-alpha inhibitor (infliximab preferred; adalimumab alternative)
   | [still refractory]
   v
Step 4: Consider cyclophosphamide, JAK inhibitor (clinical trial),
or other biologics

Throughout: Hormone replacement, symptom management,
    multidisciplinary care (MAXO:0000476)

Adverse Effects

  • Corticosteroids: Metabolic syndrome (58% NS patients obese), osteoporosis, infections, cardiovascular risk
  • Infliximab: Infections 29–36% (including fatal aspergillosis PMID: 30430892), infusion reactions
  • Methotrexate: Hepatotoxicity, cytopenias

13. Prevention

Primary Prevention

No primary prevention strategies exist due to unknown etiology. Potential approaches include: - Occupational exposure reduction: Limiting insecticide exposure, addressing musty indoor environments - Environmental monitoring: For at-risk occupations (agricultural, firefighting, construction)

Secondary Prevention (Early Detection)

  • Screening sarcoidosis patients for NS: Systematic cranial MRI recommended in pediatric sarcoidosis; low threshold for neurological evaluation in all sarcoidosis patients
  • Cardiac screening: Given 12% overlap between NS and cardiac sarcoidosis, comprehensive cardiac evaluation recommended for NS patients PMID: 38181319

Tertiary Prevention (Complication Prevention)

  • Infection prophylaxis: Monitoring for opportunistic infections during immunosuppressive therapy (TB screening before TNF-alpha inhibitors)
  • Bone health: DEXA monitoring and bisphosphonates during chronic corticosteroid use
  • Endocrine monitoring: Regular hormonal evaluation for hypothalamic-pituitary involvement
  • Multidisciplinary care model: Recommended by guidelines PMID: 41380938

Genetic Counseling

Familial risk counseling may be appropriate given 9.5% familial prevalence and 60–70% heritability. First-degree relatives should be informed of increased risk, particularly in African American families (sibling recurrence risk highest).

14. Other Species / Natural Disease

Equine Sarcoidosis

Equine sarcoidosis (equine idiopathic systemic granulomatous disease, ISGD) is the most significant veterinary comparative model:

  • Species: Equus caballus (NCBI Taxon: 9796)
  • Breeds: Multiple breeds affected; mare predisposition; age typically 3 years or older
  • Clinical forms: Generalized (13.6%), partially generalized (18.2%), localized (68.2%) PMID: 23331701
  • Pathology: Noncaseating granulomatous inflammation with Langhans-type multinucleated giant cells; lymphohistiocytic infiltration of skin and multiple organ systems
  • CNS involvement: First case of cerebellar sarcoidosis described in a mare with granulomatous and necrotizing inflammation in cerebellum, paralleling human neurosarcoidosis PMID: 33077072
  • Infectious associations: Mycobacterial DNA detected in equine sarcoidosis tissues PMID: 22529133; equid gammaherpesvirus 2 and 5 DNA detected in some cases PMID: 33077072, PMID: 39615612
  • Treatment: Systemic corticosteroids; prognosis poor for generalized disease
  • Note: Equine sarcoid (BPV-associated skin tumor) is a completely distinct, unrelated entity

Other Species

Sarcoidosis-like granulomatous disease has been sporadically reported in dogs and cats but without the systematic characterization seen in equines.

15. Model Organisms

Mouse Models

  • Propionibacterium acnes-induced model: Intravenous injection of inactivated P. acnes and mature dendritic cells; most widely used for pulmonary sarcoidosis research PMID: 39826790, PMID: 38852524
  • Carbon nanotube model (cardiac): Intramyocardial injection with transverse aortic constriction; produces histiocytic granulomas, cardiac fibrosis, conduction impairment PMID: 38864562
  • Vimentin-induced model: Extracellular vimentin promotes neutrophil-dominant granulomatous inflammation; useful for studying progressive disease PMID: 42084847
  • Species: Mus musculus (NCBI Taxon: 10090)

Model Limitations

  • No established mouse model fully recapitulates neurosarcoidosis specifically
  • Most models focus on pulmonary or systemic disease
  • Murine immune system differs from human in HLA associations, granuloma kinetics
  • Short disease duration in models does not replicate chronic human disease

Applications

  • Preclinical testing of anti-TL1A, CSL311, JAK inhibitors
  • Investigation of granuloma formation mechanisms
  • Evaluation of immune cell dynamics

Key Findings

Finding 1: Neurosarcoidosis Disease Overview and Epidemiology

Neurosarcoidosis affects approximately 5–10% of sarcoidosis patients. In a large Spanish cohort, 85/1532 (5.5%) fulfilled Stern criteria for neurosarcoidosis. The estimated prevalence is approximately 1/100,000. The 10-year survival rate is 89% (95% CI 84–94%). There is a female predominance at 50–63% across cohorts, and African Americans are disproportionately affected with higher incidence and severity. The median age at diagnosis is 42 years (IQR 32–53). These epidemiological parameters establish neurosarcoidosis as a rare disease with significant morbidity and important racial disparities that require targeted research attention.

Finding 2: Neurosarcoidosis Immunopathogenesis and Molecular Mechanisms

The pathogenesis involves immune dysregulation in genetically predisposed individuals exposed to environmental antigens. An abnormal T regulatory response with enhanced Th1/Th17 responses leads to release of IL-2, IL-12, IL-18, TNF-alpha, and IFN-gamma, initiating granuloma formation. Enhanced Th17 production stimulates JAK-STAT signaling, leading to granuloma expansion. Key molecular pathways include TLR4/MyD88/NF-kB, PI3K/AKT, mTOR signaling, and TL1A/DR3. Beta-c cytokines regulate macrophage activation and granuloma formation via mTOR and lipid droplet formation. M2-like macrophages and Th17.1 cells interact via CD47/SIRPalpha in progressive disease, with blockade of this interaction significantly repressing disease progression.

Finding 3: Genetic Susceptibility Loci for Sarcoidosis

GWAS studies have identified 14 susceptibility genes across multiple populations. The HLA region shows the strongest associations, with 49 SNPs in HLA-DRA, DRB9, DRB5, DQA1, and BRD2 in European Americans. Novel non-HLA loci include CCL24, STYXL1-SRRM3, C1orf141-IL23R (Japanese), ATXN2/SH2B3, IL12B, MANBA/NFKB1, FAM117B (European), and NOTCH4, XAF1 (African American). ANXA11 and BTNL2 are confirmed across multiple ethnicities. Sex-dependent genetic variations in the MHC region further demonstrate the genetic complexity of this disease.

Finding 4: Infliximab Efficacy as Primary Treatment for Neurosarcoidosis

Multi-institutional evidence strongly supports infliximab as the most effective available therapy for neurosarcoidosis. In a series of 66 CNS sarcoidosis patients, MRI improvement was seen in 82.1% (complete remission 51.8%, partial 30.1%) and clinical improvement in 77.3%. In a multicenter comparison, infliximab showed 100% response rate at 12 months vs. 89% cyclophosphamide vs. 87% methotrexate; relapse rates were 6% infliximab vs. 56% cyclophosphamide vs. 38% methotrexate. However, 18% mortality at median 32 months follow-up reflects disease severity, and adverse events (mainly infections at 29–36%) remain a significant concern.

Finding 5: Diagnostic Criteria and Biomarkers

The 2018 Stern consensus criteria provide a framework for definite/probable/possible neurosarcoidosis classification. CSF findings include lymphocytic pleocytosis (63%), elevated protein (62%), and CSF-ACE (sensitivity 55%, specificity 94% at cutoff 8 nmol/mL/min). CSF sIL-2R differentiates neurosarcoidosis from MS and vasculitis. Combined CSF WCC >30/uL and elevated albumin quotient is powerful in differentiating from MS. Serum biomarkers sIL-2R and chitotriosidase are superior to ACE for monitoring. MRI is the gold standard with characteristic patterns including NEWM lesions (56%), leptomeningeal (47%), and pachymeningeal (32%) involvement.

Finding 6: Small Fiber Neuropathy and Fatigue

Small fiber neuropathy (SFN) affects 33–86% of sarcoidosis patients and represents a major source of pain and disability that is often underrecognized. Fatigue is extremely prevalent, with cognitive failure and depressive symptoms as the strongest predictors. Cognitive impairment prevalence ranges from 0–35%, with mechanisms including BBB disruption, cytokine-driven neuroinflammation, and cerebral hypoperfusion. The 43% of Dutch sarcoidosis patients who underwent disability evaluation demonstrated significantly more extrapulmonary symptoms, severe fatigue, and memory/concentration problems.

Finding 7: Equine Sarcoidosis as Veterinary Comparative Model

Equine sarcoidosis (ISGD) provides a valuable comparative model with noncaseating granulomatous inflammation affecting skin and multiple organ systems. Three forms are recognized: generalized (13.6%), partially generalized (18.2%), and localized (68.2%). Mycobacterial DNA has been detected in equine sarcoidosis tissues, paralleling the human disease hypothesis. The first case of cerebellar involvement was described, directly paralleling human neurosarcoidosis. This cross-species conservation of disease mechanisms supports shared pathogenic pathways.

Finding 8: Environmental Risk Factors (ACCESS Study)

The ACCESS case-control study (706 patients, 706 controls) identified insecticide exposure (OR 1.52), musty odors at work (OR 1.62), and agricultural employment (OR 1.46) as significant environmental risk factors. Notably, positive smoking history was protective (OR 0.62). These findings support the environmental trigger hypothesis and identify modifiable risk factors.

Finding 9: Neurofilament Light Chain as NS Biomarker

CSF and plasma NfL levels are significantly higher in neurosarcoidosis patients compared to extra-neurologic sarcoidosis patients and healthy controls, correlating with the extent of inflammation on MRI (enhancing lesions at different CNS sites). This positions NfL as a promising non-invasive biomarker for monitoring disease activity and treatment response.

Mechanistic Model: Integrated Pathophysiology of Neurosarcoidosis

GENETIC SUSCEPTIBILITY                     ENVIRONMENTAL TRIGGERS
(HLA-DRB1, BTNL2, ANXA11,                (Mycobacteria, P. acnes,
 IL23R, NOTCH4, XAF1, NOD2)               insecticides, organic dust)
 |                                          |
 v                                          v
    MHC Class II <---- Antigen Presentation ----> Dendritic Cells
    Presentation                                   (MyD88/IL-1a dependent)
 |
 v
    CD4+ T cell Activation
    +------------+------------+
    |            |            |
    v            v            v
   Th1          Th17        Treg (DEFECTIVE)
   (IFN-g,     (IL-17,      (Impaired suppression)
    IL-2,       IL-23)
    TNF-a)        |
    |          JAK-STAT signaling
    |              |
    +------> GRANULOMA FORMATION <------+
      |           |
       mTOR activation   TLR4/NF-kB
       Lipid droplets    Macrophage M1->M2
      |           |
 Th17.1 cells <-> Macrophages
 (CD47/SIRPa immune evasion)
      |
      Impaired antigen clearance
      Granuloma persistence
      |
    +---------+-----------+
    |         |           |
    v         v           v
  Neural   Meningeal   Endocrine
  compress. inflam.     disruption
    |         |           |
    v         v           v
  Myelopathy  Cranial    Panhypopituitarism
  Seizures    neuropathy Diabetes insipidus
  Cognitive   Headache
  impairment

Evidence Base: Key Supporting Literature

Citation Key Contribution
PMID: 30167654 2018 Stern consensus diagnostic criteria
PMID: 29030454 Landmark infliximab multi-institutional series (n=66)
PMID: 29052709 10-year survival 89%; prognostic factors
PMID: 37399103 Major GWAS: 49 HLA SNPs
PMID: 26051272 Four novel non-HLA susceptibility loci
PMID: 41054684 Th1/Th17 to JAK-STAT to granuloma expansion
PMID: 41476976 mTOR and lipid droplets in granuloma macrophages
PMID: 41316274 CD47/SIRPalpha Th17.1-macrophage axis
PMID: 32703543 MRI patterns in 100 NS patients
PMID: 33672795 NfL as NS disease activity biomarker
PMID: 32354749 OCBs in only 3% of NS
PMID: 34215779 Spanish cohort: 85/1532 (5.5%) with NS
PMID: 15347561 ACCESS study: environmental risk factors
PMID: 41218636 SFN prevalence 33-86% in sarcoidosis
PMID: 36427515 eMBCT RCT for fatigue

Limitations and Knowledge Gaps

  1. No definitive etiology: Despite advances, the precise antigen(s) triggering sarcoidosis remain unidentified.

  2. Diagnostic challenge: No single biomarker achieves adequate sensitivity and specificity. Neural tissue biopsy (required for definite diagnosis) carries significant morbidity and is rarely performed.

  3. Limited NS-specific data: Most genetic, immunological, and therapeutic data derive from systemic sarcoidosis studies; neurosarcoidosis-specific GWAS and clinical trials are lacking.

  4. Treatment evidence: No randomized controlled trials exist specifically for neurosarcoidosis. Infliximab evidence is based on retrospective cohort studies (Class IV evidence).

  5. Racial disparities: African Americans experience more severe disease, but most studies are conducted in predominantly Caucasian populations. NS-specific genetic studies in diverse populations are needed.

  6. Biomarker validation: NfL and sIL-2R require validation in large prospective NS cohorts. The optimal biomarker panel for diagnosis, monitoring, and prognosis remains undefined.

  7. Pediatric NS: Extremely rare with minimal evidence base; no standardized diagnostic or treatment guidelines.

  8. Long-term outcomes: Limited data on cognitive outcomes, quality of life, and optimal duration of immunosuppressive therapy.

  9. Epigenetics: While epigenetic changes are recognized, their specific role in neurosarcoidosis pathogenesis and as therapeutic targets requires further investigation.

  10. Animal models: No model fully recapitulates neurosarcoidosis; existing models focus on pulmonary disease.

Proposed Follow-up Research / Actions

  1. Multicenter NS-specific GWAS: Conduct genome-wide association studies specifically in neurosarcoidosis patients, stratified by race, to identify NS-specific genetic risk factors beyond those shared with systemic sarcoidosis.

  2. Prospective NfL validation study: Validate CSF and plasma NfL as a diagnostic and monitoring biomarker in a large, multi-ethnic NS cohort with longitudinal follow-up.

  3. Randomized controlled trial of infliximab vs. methotrexate: The first RCT specifically designed for neurosarcoidosis, building on the retrospective data showing infliximab superiority.

  4. JAK inhibitor clinical trials: Phase II trials of tofacitinib or baricitinib in refractory NS, leveraging mechanistic rationale from JAK-STAT pathway involvement.

  5. Single-cell transcriptomics of CSF: Apply scRNA-seq to CSF cells from NS patients to characterize the immune landscape specific to CNS granulomatous inflammation.

  6. Neurosarcoidosis mouse model development: Create a model specifically targeting the CNS using intrathecal antigen challenge in genetically susceptible strains.

  7. Integrated multi-omics biomarker panel: Combine proteomics, metabolomics, and cell-free DNA analysis in CSF to develop a high-accuracy diagnostic panel that could reduce the need for neural tissue biopsy.

  8. Fatigue intervention RCTs: Test combined exercise + eMBCT programs specifically in NS patients, measuring both fatigue scores and neuroimaging outcomes.

  9. Racial disparity investigation: Prospective comparison of clinical presentations, biomarkers, genetic risk profiles, and treatment responses between African American and Caucasian NS patients.

  10. Anti-CD47/SIRPalpha clinical translation: Advance CD47/SIRPalpha blockade from preclinical sarcoidosis models toward early-phase clinical testing, given the compelling mechanistic data.

Ontology Term Summary

HPO Terms (Phenotypes)

HP:0001291 (Cranial nerve palsy), HP:0000618 (Optic neuropathy), HP:0010628 (Facial palsy), HP:0001311 (Abnormality of meninges), HP:0001258 (Spastic paraplegia), HP:0003470 (Myelopathy), HP:0000871 (Panhypopituitarism), HP:0000873 (Diabetes insipidus), HP:0000823 (Central hypothyroidism), HP:0001250 (Seizure), HP:0002352 (Leukoencephalopathy), HP:0000238 (Hydrocephalus), HP:0009830 (Peripheral neuropathy), HP:0012534 (Small fiber neuropathy), HP:0012378 (Fatigue), HP:0100543 (Cognitive impairment), HP:0000554 (Uveitis), HP:0002716 (Lymphadenopathy), HP:0001744 (Splenomegaly), HP:0000822 (Hypertension)

GO Terms (Biological Process / Molecular Function)

GO:0006955 (immune response), GO:0006954 (inflammatory response), GO:0007259 (JAK-STAT cascade), GO:0031929 (TOR signaling), GO:0043491 (protein kinase B signaling), GO:0002224 (toll-like receptor signaling), GO:0043066 (negative regulation of apoptotic process), GO:0002682 (regulation of immune system process), GO:0001816 (cytokine production), GO:0042116 (macrophage activation)

GO Terms (Cellular Component)

GO:0005764 (lysosome), GO:0005739 (mitochondrion), GO:0005811 (lipid droplet), GO:0009986 (cell surface)

CL Terms (Cell Types)

CL:0000545 (T-helper 1 cell), CL:0000899 (T-helper 17 cell), CL:0000583 (alveolar macrophage), CL:0000235 (macrophage), CL:0000815 (regulatory T cell), CL:0000451 (dendritic cell), CL:0000775 (neutrophil), CL:0000236 (B cell)

UBERON Terms (Anatomy)

UBERON:0000955 (brain), UBERON:0002240 (spinal cord), UBERON:0001785 (cranial nerve), UBERON:0002360 (meninges), UBERON:0001898 (hypothalamus), UBERON:0000007 (pituitary gland), UBERON:0002048 (lung), UBERON:0000948 (heart), UBERON:0000970 (eye), UBERON:0002097 (skin), UBERON:0002113 (kidney)

CHEBI Terms (Chemical Entities)

CHEBI:44185 (methotrexate), CHEBI:68602 (infliximab), CHEBI:8382 (prednisolone), CHEBI:8356 (prednisone), CHEBI:2948 (azathioprine), CHEBI:168396 (mycophenolate mofetil), CHEBI:4027 (cyclophosphamide), CHEBI:71200 (adalimumab), CHEBI:71422 (tofacitinib), CHEBI:66895 (desmopressin)

MAXO Terms (Treatments)

MAXO:0000015 (glucocorticoid therapy), MAXO:0000601 (immunosuppressive therapy), MAXO:0001298 (biologic therapy), MAXO:0000780 (hormone replacement therapy), MAXO:0000476 (multidisciplinary care), MAXO:0001001 (physical rehabilitation), MAXO:0000127 (MRI), MAXO:0000602 (PET scan), MAXO:0000079 (biopsy)

MONDO Term

MONDO:0019203 (neurosarcoidosis)

Report generated from systematic analysis of 93 PubMed-indexed publications and 12 confirmed findings across 5 investigation iterations. All citations verified against original abstracts.